预约演示
更新于：2026-09-28
Rilpivirine Hydrochloride
盐酸利匹韦林
更新于：2026-09-28
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2011-05-20), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C22H19ClN6 |
InChIKeyKZVVGZKAVZUACK-BJILWQEISA-N |
CAS号700361-47-3 |
关联
121
项与 盐酸利匹韦林 相关的临床试验NCT07637942
Phase IV Study of the Pharmacokinetics of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women With HIV in the United States
Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.
开始日期2026-10-15 |
NCT07688369
A Phase 1, Double-blinded, Randomised, Active Controlled, Clinical Trial to Assess the Reactogenicity, Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine. The design of the study is double-blinded, randomised and active controlled. The active controlled product is considered the commercially available vaccine (IPOL).
开始日期2026-07-01 |
NCT07650916
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents With HIV Who Are Virologically Suppressed on ART
This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).
开始日期2026-06-25 |
申办/合作机构 |
100 项与 盐酸利匹韦林 相关的临床结果
登录后查看更多信息
100 项与 盐酸利匹韦林 相关的转化医学
登录后查看更多信息
100 项与 盐酸利匹韦林 相关的专利（医药）
登录后查看更多信息
1,813
项与 盐酸利匹韦林 相关的文献（医药）2026-12-31·HIV Research & Clinical Practice
Successful initiation of fully parenteral antiretroviral therapy in a treatment-naïve person with HIV-1 infection and intestinal failure
Article
作者: Sram, Krystof ; Lhotan, Jakub ; Jilich, David ; Sevela, Stanislav ; Rozsypal, Hanus
INTRODUCTION:
In patients with severe surgical and gastrointestinal complications, standard oral combination antiretroviral therapy (ARV) may be temporarily impossible. Long-acting cabotegravir/rilpivirine (CAB/RPV LA) is approved for virologically suppressed individuals pretreated with oral therapy, but data on its use in treatment-naïve, critically ill patients with absent enteral absorption are extremely limited.
CLINICAL PRESENTATION:
We report a 26-year-old male admitted with fulminant hypertriglyceridaemic necrotizing pancreatitis complicated by abdominal compartment syndrome, multiple laparotomies, open abdomen with enteric fistulae, short bowel syndrome type I, chronic intestinal failure requiring parenteral nutrition, portal vein thrombosis, and prolonged intensive care. HIV-1 infection was diagnosed early (HIV RNA 5,000 copies/mL; CD4+ 780 cells/µL). Within three months, HIV RNA rose to 320,000 copies/mL and CD4+ declined to 570 cells/µL. Given absent gastrointestinal passage, standard ARV was initially deferred, but rapid virological rebound necessitated urgent treatment. An off-label fully parenteral regimen was initiated: intravenous zidovudine (AZT) with intramuscular CAB/RPV LA. Therapy was well tolerated alongside surgery, parenteral nutrition, antimicrobials, and anticoagulation. HIV RNA decreased to <20 copies/mL within 65 days and remained suppressed, with CD4+ recovery. Intravenous AZT was discontinued after 35 days, and CAB/RPV LA continued as maintenance during recovery and home parenteral nutrition.
DISCUSSION:
Fully parenteral ARV, including CAB/RPV LA, may provide a safe and effective bridge to durable viral suppression in patients with absolute contraindications to oral therapy, warranting further evaluation.
2026-11-01·INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Pharmacogenomic variability in adolescents and youth with virologic rebound while receiving injectable cabotegravir/rilpivirine: A multi-case series
Article
作者: Howze, Timothy J ; Carr, Susan D ; Patel, Nehali D
BACKGROUND:
Long-acting injectable cabotegravir and rilpivirine (LAI-CAB/RPV) has transformed human immunodeficiency virus (HIV) treatment by providing durable viral suppression without daily oral antiretroviral therapy (ART). Although clinical trials have demonstrated excellent efficacy, real-world experience has identified rare cases of viral blips, persistent low-level viremia and virologic rebound, with underlying mechanisms remaining unclear.
METHODS:
We conducted a retrospective case series of 10 adolescents and young adults with HIV who developed virologic abnormalities after transitioning from suppressive oral ART to LAI-CAB/RPV. Among 76 patients receiving LAI-CAB/RPV during the study period, 11 developed virologic abnormalities and 10 underwent pharmacogenomic (PGx) testing. Clinical, virologic and PGx findings were reviewed.
FINDINGS:
All patients experienced viral suppression before initiating LAI-CAB/RPV. Following the transition, all experienced viral blips, six developed persistent low-level viremia and one progressed to virologic failure. Eight patients had CYP2B6 intermediate or poor metabolizer phenotypes, seven had clinically relevant CYP2C19 variants, and nine had CYP3A5 variants. All patients demonstrated at least one non-normal metabolizer phenotype, and most exhibited variability across multiple metabolic pathways.
INTERPRETATION:
This case series identifies clustering of multiple pharmacogenomic variants among patients experiencing virologic abnormalities while receiving LAI-CAB/RPV. Although these variants are relatively common individually, their combined occurrence warrants further investigation. Prospective pharmacokinetic and pharmacogenomic studies are needed to determine whether host genetic variability contributes to long-acting ART outcomes.
2026-10-01·INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
CABO–CHANCE study: A real-life world study of cabotegravir plus rilpivirine long-acting intramuscular in ART-experienced people with HIV
Article
作者: Romero, Alberto ; García-Aguilera, Maria ; López, Teresa ; Martinez, Onofre ; García-Ocaña, Paula ; Ruiz-Sancho, Andres ; Moreno, Santiago ; Bernal, Enrique ; Rivero, Antonio ; López-Lirola, Ana ; Hidalgo-Tenorio, Carmen ; Santos, Ignacio De Los ; Sorni, Patricia ; Omar, Mohamed ; Sanjoaquín, Isabel ; Blanco, Jose Ramon ; Garcia, Coral
BACKGROUND:
This study of people with HIV (PWH) receiving CAB + RPV LAI evaluated its effectiveness, safety, and impact on inflammatory markers, body fat/lean mass distributions, quality of life, sleep, health satisfaction, and stigma experience over 1 y.
METHODS:
A prospective, longitudinal, multicentre study was conducted in 15 hospitals and enrolled between June 2023 and January 2024. It included virologically suppressed PWH (HIV-1 RNA <50 c/mL for ≥6 months) switched from oral antiretroviral therapy to CAB + RPV LAI. Anthropometrics, CD4/CD8 counts, viral load, creatinine clearance, lipid levels, and inflammatory markers were recorded at baseline and 12, 28, 52 weeks. Patient-reported outcomes were gathered using the WHOQOL-HIV-BREF, HIV stigma scale for use in Spain, Pittsburgh Sleep Quality Index, and questionnaires on health satisfaction and adverse events. A subpopulation underwent to whole-body dual energy X-ray absorptiometer (DEXA).
RESULTS:
Among 269 PWH (mean age 45.6 y; 89.2% male), 240 completed 52-week follow-up, 14 (5.2%) were lost to follow-up, six (2.2%) withdrew consent, 5 (1.9%) were discontinued for adverse events, and one (0.4%) had virological failure (week 12). Snapshot effectiveness was 88.8% (intention-to-treat) and 97.5% (per-protocol). No oral bridging was required. CD4/CD8 ratio (P = 0.0001) and creatinine clearance (P = 0.0001) increased, d-dimer decreased at week 12 (P = 0.001), and BMI modestly increased (P = 0.046). No changes in total/regional fat or lean mass by DEXA (n = 56). Stigma (P = 0.029) and adverse events (P = 0.001) improved.
CONCLUSIONS:
In this real-world cohort, CAB + RPV LAI was highly effective and safe, was associated with a possible favourable immunologic response, a transient reduction in inflammation, and reduced perceived stigma over 1 y.
445
项与 盐酸利匹韦林 相关的新闻（医药）2026-09-26
·宇川科讯
🌐2026年09月26日（星期六）
每日｜科研进展｜技术动态｜产业政策｜科技人物｜期刊成果｜科技金融 ｜
🔥【今日头条】
谷歌宣布发射搭载自研TPU芯片Suncatcher原型卫星——谷歌将于10月1日搭乘SpaceX Transporter-18任务发射首颗搭载4颗自研Trillium TPU芯片的原型卫星，启动“太阳捕手”项目首次在轨验证，测试AI芯片在太空极端环境下的生存与散热能力，探索近地轨道太空数据中心可行性。（来源：TechSpot，2026-09-25）
📋【每日重要新闻TOP11摘要】
1.【前沿技术应用动态】谷歌发射搭载4颗自研TPU芯片的Suncatcher原型卫星——首次在轨测试AI硬件在太空极端环境下的生存与散热能力，探索近地轨道太空数据中心可行性。（来源：TechSpot，2026-09-25）
2.【前沿科技金融动态】Cohere与Aleph Alpha达成200亿美元最终合并协议——组建跨大西洋主权AI企业，双总部设在多伦多与柏林，整合企业级大模型与欧洲政府客户资源。（来源：150sec，2026-09-25）
3.【国别科技政策摘要】美国上诉法院裁定维持将Anthropic列入国防供应链黑名单——禁止美军及国防承包商使用Claude模型，Anthropic表示将评估后续法律救济途径。（来源：C4ISRNET，2026-09-25）
4.【产业前沿科技新闻】特斯拉Optimus人形机器人产能加速爬坡——截至8月已达每周生产数百台规模，较二季度每周数十台翻约10倍，计划年底前建成连续自动化产线。（来源：财联社，2026-09-26）
5.【前沿科学研究进展】XENONnT暗物质探测器首次探测到太阳pp中微子最低能信号——将直接中微子观测能阈推至历史最低约17keV，为研究太阳核心聚变及轻质量暗物质提供新窗口。（来源：芝加哥大学，2026-09-24）
6.【重要科技期刊成果】《NEJM》anito-cel CAR-T疗法治疗复发难治骨髓瘤全部38例获缓解——基于合成d结构域的BCMA靶向疗法，严重细胞因子释放综合征与免疫神经毒性罕见，安全性可控。（来源：NEJM，2026-09-24）
7.【前沿科技工程项目】CERN正式启动大型强子对撞机长停机3期拆卸工程——27公里隧道内数千块磁铁开始分批拆除，为升级高亮度LHC腾出空间，整个升级工程预计持续四年。（来源：CERN，2026-09-17）
8.【前沿科技人物动态】法国物理学家Jacqueline Bloch荣获2026年CNRS金奖——表彰其在极化激元光物相互作用杂化粒子领域的开创性发现，研究横跨石墨烯物性与黑洞类比物理。（来源：CNRS，2026-09-17）
9.【前沿学术活动信息】2026世界工程教育论坛WEEF在哥伦比亚卡塔赫纳举行——开设“用AI变革包容性STEM教育”等工作坊，推动拉美与全球工程教育创新协作。（来源：WEEF组委会，2026-09-24）
10.【最新科技产品资讯】微软推出新版Copilot新增Home、Code和Autopilot三项核心能力——将AI助手从对话工具扩展为可执行任务、构建应用和持续工作的智能代理。（来源：界面快讯，2026-09-25）
11.【国别科技新闻资讯】以色列宣布五年内打造“全球第三大人工智能强国”——总理内塔尼亚胡在联合国大会期间宣布，加大AI研发投入与人才引进力度，追赶中美两国。（来源：环球时报，2026-09-23）
🔬【一、前沿科学研究进展】
1. 位于意大利格兰萨索地下的XENONnT暗物质探测器首次探测到能量低至约17keV的太阳pp中微子与电子散射信号——将直接中微子观测能阈推至历史最低，为研究太阳核心聚变及轻质量暗物质提供新窗口。（来源：芝加哥大学，2026-09-24）
2. 中科院合肥物质院团队发现趋磁细菌AMB-1——可将秀丽隐杆线虫平均寿命延长43.39%，同时保护神经与肠道健康，机制为抑制铁死亡相关脂质过氧化，为微生物抗衰老干预提供全新策略。（来源：SciTechDaily，2026-09-24）
3. 丹麦奥胡斯大学团队联合国际同行在《自然·生物医学工程》发表研究——开发出约300纳米直径的石墨相氮化碳空心光敏颗粒，注射至视网膜色素变性盲鼠眼内可激活残存神经节细胞，视觉皮层记录到光信号并改善行为反应。（来源：Neuroscience News，2026-09-22）
4. 英国维康桑格研究所与剑桥大学团队在《自然》发文——发现人类精子中相当比例非交叉基因转换发生在减数分裂之前的有丝分裂阶段，携带类似体细胞DNA修复特征，改写遗传多样性起源的传统认知。（来源：Wellcome Sanger Institute，2026-09-25）
5. 崖州湾实验室与华中农大团队联合牛津、慕尼黑大学在《科学》发文——分析745个欧亚野猪基因组后发现现代野猪源自南亚而非东南亚岛屿，约300至500万年前古老猪科基因渐渗引入约43Mb X染色体单倍型。（来源：新华网，2026-09-25）
6. 日本东北大学与千叶大学团队开发出异山梨醇基生物塑料增塑剂——添加至聚碳酸酯后柔韧性提升逾十倍，废弃后经氨处理可转化为尿素和异山梨酯肥料组分，盆栽验证可促进菠菜生长，同时应对塑料废弃物与肥料能耗双重挑战。（来源：Tohoku University，2026-09-14）
7. 国际研究团队在《自然·通讯》发表高分辨率成像研究——首次观察到减数分裂中父本与母本染色体并非平滑靠近，而是在特定细胞分裂阶段以跳跃式快速完成配对联会，揭示了同源染色体识别与重组的全新动态机制。（来源：Gazeta.ru，2026-09-24）
8. 美国蒙大拿州立大学团队在《自然·化学生物学》发文——发现哺乳动物细胞存在半胱氨酸合成的备份生存途径，即使两大主要二硫化物还原系统失活仍可生成必需氨基酸，该机制与癌细胞耐药存活密切相关。（来源：Agentic Tribune，2026-09-25）
9. 美国密苏里大学团队在《临床研究杂志》发文——发现衰老中神经肌肉接头传递可靠性下降源于NaV1.4蛋白减少，动物实验显示抑制ClC-1氯离子通道可恢复老年肌肉功能并提升肌力约14%。（来源：ScienceDaily，2026-09-24）
10. 中科院福建物质结构研究所团队在光学活性铁电材料中实现电可控圆偏振光探测，同时观测到面内与面外极化分量——通过翻转电场可动态切换探测手性方向，为新型片上光存储与量子光信息器件提供材料新方案。（来源：Chinese Academy of Sciences，2026-09-24）
⚙️【二、前沿技术应用动态】
1. 法国Quobly在STMicroelectronics 300毫米硅工艺线QSOI芯片上首次单片集成量子比特读出与单、双比特门操作——验证量子与经典电路共集成路线，为硅自旋量子计算机量产奠定工艺基础。（来源：Quobly，2026-09-16）
2. 谷歌宣布下周通过SpaceX Transporter-18任务发射Suncatcher原型卫星——搭载4颗自研TPU芯片，首次在轨测试AI硬件承受发射振动、辐射与极端温度能力，探索近地轨道太空数据中心。（来源：TechSpot，2026-09-25）
3. 法国Symbio公司在2026汉诺威商用车展上发布第三代氢燃料电池电堆——针对重型交通与固定式发电场景优化，功率密度与耐久性显著提升，系统效率超过58%，为长途物流与港口机械零碳化提供核心动力模块。（来源：Hydrogen Central，2026-09-14）
4. 新加坡南洋理工大学团队开发出仿生人工光催化叶片装置——可直接利用阳光从污染海水中制取绿氢，同时降解工业废水中高毒性肼污染物，无需外部电源即可运行，相关成果发表于《自然·通讯》。（来源：pv magazine，2026-09-18）
5. 2026世界新能源汽车大会发布11项创新技术成果——涵盖第二代刀片电池全域极速快充、400kW商用车燃料电池、耐低温锰基混合固液电池、EMB电控机械制动及高算力AI芯片平台等方向。（来源：海南日报，2026-09-24）
6. 德国弗劳恩霍夫ISE开发出光伏与电解槽耦合组件——利用多结太阳电池高光电压直接驱动电解水，户外演示实现31.3%的太阳能到化学能转换效率，为分布式绿氢生产提供高效紧凑一体化方案。（来源：Fraunhofer ISE，2026-09-09）
7. 美国EPB在查塔努加量子中心启用IonQ Forte企业级量子计算机——造价约2200万美元，首次将商业量子计算与216光纤量子网络整合于同一设施，成为美国首个量子计算与通信协同商业枢纽。（来源：PR Newswire，2026-09-18）
8. 日本东京光学量子计算企业OptQC获三菱电机旗下创新基金投资——已交付首套商用光量子计算系统，此前完成由NTT领投的4700万美元A2轮融资，加速光量子处理器在日本及亚太市场商业化落地。（来源：量科网，2026-09-15）
9. 新疆春玉米小面积超高产攻关取得突破——4块示范田经专家现场籽粒机收测产，折合14%水分后最高亩产达1648.99公斤，其余三块分别为1533.62、1407.24和1383.33公斤。（来源：科技日报，2026-09-22）
10. 德国弗劳恩霍夫ISE优化锂电池电极结构——在自动化干房产线验证通过调整电极孔隙率与压实密度，使电池能量密度提升10%至15%且不牺牲功率性能，该电极概念可迁移至多种电池化学体系。（来源：Fraunhofer ISE，2026-09-09）
🏗️【三、前沿工程项目新闻】
1. 欧洲核子研究中心正式启动大型强子对撞机长停机3期拆卸工程——27公里隧道内数千块二极、四极和六极磁铁中的内三重态组开始分批拆除，为升级高亮度LHC腾出空间，整个升级工程预计持续四年。（来源：CERN，2026-09-17）
2. 德国马普等离子体物理研究所Wendelstein 7-X仿星器9月15日重启OP2.4实验运行——目标在高能量输入下实现30分钟长脉冲放电，验证仿星器稳态运行能力，西班牙CIEMAT等多国团队参与。（来源：CIEMAT，2026-09-18）
3. 美国X-energy子公司TRISO-X在田纳西州橡树岭宣布TX-1先进核燃料厂主体结构封顶——这座21.4万平方英尺建筑将成为美国首座NRC II类许可TRISO燃料量产设施，计划2028年初投产。（来源：X-energy，2026-09-24）
4. 浙江宁波舟山港六横公路大桥二期双屿门特大桥完成首节钢箱梁吊装——大桥主跨1768米，为国内最大跨度跨海桥梁及世界最大跨度单跨吊钢箱梁悬索桥，全桥钢箱梁共100个节段总重超3万吨，全面进入钢梁架设阶段。（来源：中国新闻网，2026-09-15）
5. 阿塞拜疆戈布斯坦100兆瓦光伏电站正式并网发电——该项目由中国寰泰能源投资建设，位于巴库附近，是中阿新能源合作的标志性项目，投产后将显著提升阿塞拜疆可再生能源发电占比。（来源：中国一带一路网，2026-09-17）
6. 中国振华石油投资建设的伊拉克东巴油田天然气处理装置顺利投产——伊拉克石油部长出席投产仪式，该装置将有效回收伴生气，减少火炬燃烧排放，是中伊能源工程合作的重要进展。（来源：中国一带一路网，2026-09-23）
7. 欧洲投资银行向立陶宛克莱佩达港提供1亿欧元贷款——支持该港改造为波罗的海地区国防与清洁能源枢纽，升级码头、航道与液化气体基础设施，强化欧盟东部海上能源与贸易通道韧性。（来源：欧盟委员会能源总司，2026-09-15）
8. 国网新源辽宁兴城抽水蓄能电站上水库大坝顺利填筑至470米高程——标志上水库主体工程进入加速阶段，电站建成后将承担辽宁电网调峰调频与新能源消纳任务。（来源：辽宁省人民政府，2026-09-21）
9. 英国原子能管理局位于卡勒姆的Sunrise聚变专用AI超级计算机于9月开始运行——号称全球功率最强的聚变专用AI超算，用于加速聚变反应堆等离子体模拟与材料设计，是英国政府首个AI增长区核心设施。（来源：UKAEA，2026-09-15）
10. 日本QST组织JT-60SA托卡马克OP2运行战役操作人员培训周——9月14日至18日在那珂核融合研究所开展，来自欧洲各ITER参与方的工程师接受控制室操作培训，为下一阶段长脉冲高参数实验运行做准备。（来源：ITER，2026-09-14）
🎓【四、前沿学术活动信息】
1. 印度总理莫迪9月25日在新德里揭幕”环境与气候动态的未来”国际会议——会期两天，汇聚多国官员与学者围绕全球环境挑战、气候治理与机构合作展开对话，探讨强化跨境环境治理与制度协同的务实路径。（来源：MyGov India，2026-09-25）
2. 第九届中国—东南亚国家海洋合作论坛9月24日至25日在泰国曼谷举行——由中国自然资源部与泰国自然资源与环境部海洋与海岸厅共同主办，围绕海洋可持续管理、蓝色经济与防灾减灾展开双边及多边磋商。（来源：中国-东南亚海洋合作论坛组委会，2026-09-24）
3. 第25届”生命科学促进可持续发展”国际会议9月24日至26日在罗马尼亚克卢日-纳波卡农业科学与兽医大学举行——聚焦食品科学、农业生物技术与生态系统服务，推动欧洲及发展中国家学者交流可持续粮食体系方案。（来源：ISEKI-Food Association，2026-09-24）
4. 第二届AI-SMART多学科国际科学会议9月23日至25日在塞尔维亚贝尔格莱德举办——以”AI赋能更智慧的明天”为主题，汇集全球学者探讨人工智能在社会科学与公共政策领域的跨学科应用。（来源：AI-SMART Conference组委会，2026-09-23）
5. 国际材料科学与工程大会MSE Congress 9月22日至24日在德国达姆施塔特工业大学举行——覆盖先进结构材料、功能薄膜与增材制造方向，汇聚学界与产业界代表展示最新研究进展。（来源：MSE Congress组委会，2026-09-22）
6. 第九届河口海岸国际研讨会9月22日至26日在中国广西钦州召开——以”从传统到人工智能：河口海岸演进与现代文明”为主题，围绕河口海岸AI技术、水沙运动模拟与智慧港航调度展开学术交流。（来源：河口海岸国际研讨会组委会，2026-09-22）
7. “中西新时代文明对话：中国式现代化的世界意义”国际学术研讨会9月26日在西班牙马德里举行——由重庆市委宣传部联合西班牙共产党举办，以中国主题图书西语版为载体，汇聚两国学者与出版界代表对话。（来源：重庆日报，2026-09-26）
8. 2026世界工程教育论坛WEEF 9月24日在哥伦比亚卡塔赫纳会议中心举行——作为工程教育领域全球性盛会，开设”用AI变革包容性STEM教育”“主动学习”等工作坊，推动拉美与全球工程教育创新协作。（来源：WEEF 2026组委会，2026-09-24）
9. 第13届电力与能源系统工程国际会议CPESE 2026于9月25日至27日在日本大阪举行——聚焦新型电力系统、储能技术与能源数字化，为亚太地区电力电子与能源工程研究者提供交流平台。（来源：CPESE 2026组委会，2026-09-25）
10. 人工智能与医学双向赋能工程科技学术研讨会暨2026年第十届临床和转化医学大会9月22日至23日在上海举办——由中国工程院医药卫生学部主办，围绕AI辅助诊疗、转化医学与医工交叉成果展开研讨。（来源：中国工程院，2026-09-22）
👤【五、前沿科技人物动态】
1. 法国物理学家Jacqueline Bloch荣获2026年法国国家科学研究中心金奖——表彰其在极化激元这一光物相互作用杂化粒子领域的开创性发现，研究横跨石墨烯物性与黑洞类比物理，她同时为法国科学院院士。（来源：CNRS，2026-09-17）
2. 美国物理学家Lindley Winslow 9月出任马普物理研究所新设”稀有事件物理”部主任——原任教麻省理工学院，专注轴子暗物质探测CUPID与DMRadio实验，领衔开发超导量子传感器与强磁场技术。（来源：马普物理研究所，2026-09-16）
3.澳大利亚昆士兰大学副校长Sue Harrison教授当选英国皇家工程院院士——该生物过程工程师深耕可持续资源管理与矿物加工三十年，为该院50周年当选的75位新院士之一，其中含创纪录的24位女性。（来源：昆士兰大学，2026-09-25）
4. 牛津大学计算机科学教授Tom Melham当选英国皇家工程院院士——他是形式化硬件验证领域的国际先驱，发展自动推理与数学方法以在芯片制造前自动发现设计缺陷，并与半导体产业开展长期深度合作。（来源：牛津大学计算机系，2026-09-24）
5. 牛津大学生物学家Alexandra Zimmermann博士荣获2026年MIDORI生物多样性奖——表彰其二十五年间在人兽冲突与共存领域的全球领导力，研究推动野生动物保护政策与社区共存实践。（来源：牛津大学MPLS学部，2026-09-16）
6. 中国科学院院士李言荣卸任西北工业大学党委书记——9月24日李言荣出现在四川大学材料科学与工程学院师资队伍名单中，这位曾任四川大学校长的电子信息材料专家已回母校任教并为学院师生作学术报告。（来源：四川大学，2026-09-24）
7. 浙江大学求是特聘教授徐德鸿荣获2026年IEEE PELS电力电子教育成就奖——成为该奖首位中国获奖者，表彰其编撰广泛使用的中英文教材并牵头电力电子教育活动，他此前已两度获该领域IEEE大奖。（来源：电能革新，2026-09-25）
8.中国工程院院士申有青不再担任浙江大学化学工程与生物工程学院院长——这一人事调整自9月25日学院官网更新后对外披露，引发高校化工学科建设关注。（来源：浙江大学化工学院，2026-09-25）
9. 国际知名心血管药理学家肖瑞平教授出任东南大学药学院创始院长——该院于2026年6月揭牌成立，依托医工交叉与人工智能优势，深耕数智赋能新药研发，打通靶点挖掘到临床转化全链条。（来源：光明社教育家，2026-09-25）
10. 高校人事调整近期集中公布——唐洪武出任中山大学校长，梅兵任天津大学党委书记，于祥成任华南理工大学党委书记，一批资深学者与管理干部履新中国重点高校领导岗位，推动办学治理与学科建设发展。（来源：中国教育在线，2026-09-24）
📖【六、重要科技期刊最新成果】
1. 《Nature》：上海中医药大学巴乾团队发现线粒体分裂因子MFF是感知调控铁死亡的专属分子开关——其Ser155磷酸化协同放大线粒体与过氧化物酶体碎裂，团队筛选出天然小分子阿维菌素B1靶向干预该通路。（来源：上海中医药大学，2026-09-26）
2. 《Cell》：广州中医药大学靳红磊、王宏斌团队揭示叶绿体经低温诱导的RAF3/6双激酶模块——其磷酸化光系统组分以抑制光合作用，同时经WHY1逆行信号激活核内抗寒基因，发现与纬度相关的进化变异。（来源：广州中医药大学，2026-09-20）
3. 《Lancet》：UCL牵头LATA试验在非洲四国476名青少年中证实——每两月注射cabotegravir/rilpivirine两年后病毒反弹率仅1%，显著优于口服药组6%，九成患者称注射更易坚持。（来源：UCL，2026-09-18）
4. 《Science》：马普动物行为所联合印尼机构发表封面论文——分析苏门答腊红猩猩近七千份幼年记录发现，幼崽社会观察与试错学习的风格组合，决定其独立生存时食谱广度，揭示人类延长童年学习的演化根源。（来源：马普学会，2026-09-24）
5. 《Nature Communications》：达姆施塔特工大团队开发新型小分子——将疾病相关蛋白与细胞内天然蛋白桥接，把细胞毒性药物定向引导至病变细胞，为降低脱靶副作用提供全新策略，已申请国际专利。（来源：达姆施塔特工业大学，2026-09-25）
6. 《NEJM》：I期试验显示anito-cel这款基于合成d结构域的BCMA靶向CAR-T疗法治疗复发难治性骨髓瘤——全部38例患者均获缓解，严重细胞因子释放综合征与免疫神经毒性罕见，安全性可控。（来源：新英格兰医学杂志，2026-09-24）
7. 《Nature Communications》：华中农大团队发现WLG基因调控DST依赖的H₂O₂稳态与气孔孔径——协调水稻对干旱、盐胁迫与病原菌多重耐受，基因编辑株系田间逆境下产量损失显著降低。（来源：华中农业大学，2026-09-24）
8. 《Lancet》：拉美多域生活方式干预认知衰退试验LatAm-FINGERS在拉丁美洲认知高危老年人中开展——通过评估饮食、运动、认知训练与社会参与的联合干预效果，为中低收入地区痴呆一级预防提供本地化证据。（来源：柳叶刀，2026-09-21）
9. 《NEJM》：III期随机试验显示，secukinumab联合24周糖皮质激素减量治疗复发型风湿性多肌痛——其缓解率显著高于单纯激素减量方案，为这一慢性炎症性疾病提供减少激素依赖的新治疗选择。（来源：新英格兰医学杂志，2026-09-24）
10. 《Science》：发表研究深入挖掘电池寿命背后隐藏的关键影响因素——通过揭示决定电池老化与衰减的微观机制，为提升储能器件循环寿命与可靠性提供新的设计思路与实验依据，标志该领域取得重要进展。（来源：Science，2026-09-24）
🏭【七、产业前沿科技新闻资讯】
1. 以色列高塔半导体与日本政府计划共同投资40亿美元——将新潟县阿贺野市闲置200毫米Fab 6工厂改造为300毫米硅光子与先进光封装产线，打造光互连半导体大型制造基地。（来源：IT时代网，2026-09-26）
2. Akamai Technologies宣布获得Anthropic七年期总额116亿美元合同承诺——通过分布式AI基础设施和云软件支持Anthropic快速增长的CPU工作负载需求。（来源：财联社，2026-09-25）
3. 韩国全南光州统合特别市公开与SK海力士、三星电子就湖南半导体集群协商资料——两家企业分别强调大规模用地保障与加快投资落地必要性，相关投资构想正逐步细化，加码韩国半导体扩产节奏。（来源：IT之家，2026-09-25）
4. 亚盛医药宣布其原创Bcl-2抑制剂Lisaftoclax（APG-2575）获美国FDA批准开展全球III期临床试验——用于既往经BTK抑制剂治疗的慢性淋巴细胞白血病患者。（来源：Clival，2026-09-25）
5. 欧洲AI云基础设施公司Nscale完成33.6亿美元可转债融资——英伟达等参与投资，资金将用于扩建其分布式AI算力基础设施，应对全球大模型训练与推理需求的爆发式增长，加速欧洲主权AI算力布局。（来源：界面新闻，2026-09-25）
6. 格芯与麻省理工学院微系统技术实验室达成合作——利用格芯22FDX超低功耗制程平台开发边缘AI芯片，集成硅光子学与RF SOI技术，边缘设备功耗降低约80%，首批流片计划年内启动。（来源：射频微波器件采购网，2026-09-25）
7. 特斯拉Optimus人形机器人产能加速爬坡——截至8月已达每周生产数百台规模，较二季度每周数十台水平翻约10倍，管理层计划年底前建成连续自动化产线，早期机型或采取只租不售商业模式。（来源：财联社，2026-09-26）
8. 印度光伏制造商Premier Energies在南部安得拉邦投产7GW太阳能电池制造厂——耗资3.437亿美元，占地101英亩，生产N型TOPCon G12R电池。（来源：新浪财经，2026-09-25）
9. 加拿大商业发展银行BDC在投资峰会上宣布10亿加元资本配置计划——其中5亿加元投入国防基金间接投资风投与私募股权，2亿加元注入StrongNorth直投早期基金，助力量子计算与深科技产业生态发展。（来源：Quantum Computing Report，2026-09-25）
10. 波兰光伏承包商ML System子公司获本地可再生能源公司BESS-Group委托承建项目——承建两座各5MW/10MWh储能设施拓展其在中东欧储能市场的工程业务版图，响应欧洲户储与工商业储快速增长需求。（来源：Renewables Now，2026-09-25）
📱【八、最新科技产品资讯】
1. 微软9月25日宣布推出新版Copilot——新增Home、Code和Autopilot三项核心能力，将AI助手从对话工具扩展为可执行任务、构建应用和持续工作的智能代理。（来源：界面快讯，2026-09-25）
2. 奕境X9正式上市推出4款车型——售价28.98万至36.98万元，作为奕境汽车与华为乾昆合作首款车型，搭载华为乾昆智驾ADS 5、896线激光雷达及鸿蒙座舱HarmonySpace 6等智能化方案。（来源：贝壳财经，2026-09-24）
3. 爱普生机器人正式发售AX6六轴协作机器人——为其首款商用六轴cobot，自9月22日起通过品牌经销商网络供货，补充此前以SCARA为主的产品线，面向中小型制造企业的柔性自动化场景。（来源：RoboActu，2026-09-23）
4. RobotPlusPlus在汉堡SMM 2026展会上发布HighMate工业维护机器人系列——涵盖工业清洗与防腐作业，其中HighMate AP-F-CO喷涂机器人搭配VOC回收系统。（来源：GlobeNewswire，2026-09-25）
5. OPPO Find X10系列9月24日全国开售——包含X10 E、X10和旗舰Pro Max三款，售价4999元起，搭载哈苏超清原相机系统支持8K视频录制，配备8000mAh超大电池与新一代护眼屏。（来源：太平洋科技，2026-09-24）
6. 尼康正式发布全画幅微单数码相机Z5 II C——采用无取景器平顶设计便于轻巧收纳，配备专用优化校准按钮支持尼康云创色彩方案，引入AUTO模式自动调整拍摄参数，定位入门级全画幅便携创作。（来源：尼康中国，2026-09-24）
7. Motorola Signature 27在高通骁龙峰会 keynote上首次亮相——为首款搭载骁龙8 Elite Extreme Gen6芯片的智能手机，配备2亿像素长焦摄像头。（来源：Kalinga TV，2026-09-24）
8. MIVI One智能手机正式发布——配备6.75英寸显示屏与6000mAh大容量电池，面向印度大众市场用户主打长续航与大屏体验，是印度本土消费电子品牌在中低端智能手机市场的最新产品布局。（来源：GSMArena，2026-09-25）
9. 技嘉发布旗舰级游戏显示器Aorus Elite FO32U24G——采用31.5英寸Tandem WOLED面板，为新一代高端电竞显示技术，面向追求极致色彩与响应速度的PC游戏玩家市场。（来源：GECID，2026-09-24）
10. 高通发布第二代骁龙Sound Elite Gen2音频芯片——面向带摄像头的智能耳机与音频眼镜设备，端侧AI算力较前代翻倍，支持更复杂的语音交互与主动降噪算法，推动智能音频可穿戴设备迈入智能体时代。（来源：GSMArena，2026-09-24）
🌍【九、国别科技新闻资讯】
1. 【新加坡】新加坡经济发展局宣布深化与应用材料、KLA、格芯等半导体巨头研发合作——在新设立先进封装与芯片制造联合研发中心，聚焦2纳米以下制程与异构集成技术，巩固新加坡全球半导体制造与研发枢纽地位。（来源：DIGITIMES，2026-09-25）
2. 【以色列】总理内塔尼亚胡在联合国大会期间宣布建设人工智能强国——拟在五年内将以色列打造成“全球第三大人工智能强国”，追赶中美两国，加大AI研发投入与人才引进力度，巩固以色列在全球科技版图中的地位。（来源：环球时报，2026-09-23）
3. 【玻利维亚】玻利维亚与西班牙电信卫星公司Hispasat签署谅解备忘录——启动卫星连接试点项目，作为欧盟”全球门户”投资战略的一部分，旨在提升玻利维亚偏远地区的宽带覆盖与数字接入能力。（来源：ABC Color，2026-09-25）
4. 【马来西亚】新加坡量子计算初创公司AQSolotl在柔佛新山的UTM Technovation Park设立研发中心——专注设计与生产高精度量子计算机控制电子设备，打造马新跨境人才与商业化走廊。（来源：Quantum Computing Report，2026-09-25）
5. 【丹麦】哥本哈根量子铸造厂与诺和诺德基金会宣布先进制造项目——将在哥本哈根建设一座占地5300平方米的量子芯片制造设施，开发并规模化下一代量子芯片所需的先进制造设备，增强欧洲在全球量子竞争中的地位。（来源：量科网，2026-09-25）
6. 【英国】欧盟委员会一项安全提案拟以知识产权管控为由，限制英国参与Horizon Europe量子计算旗舰项目——19个成员国与学术界对此表示反对，担忧此举将削弱欧洲在量子技术领域的整体竞争力。（来源：London Daily，2026-09-25）
7. 【澳大利亚】昆士兰州Bungaban风光储一体化项目获联邦环境审批——该项目整合大型风电、光伏与电池储能系统，为澳东海岸可再生能源转型标志性项目，助力昆州2035年实现100%可再生能源目标。（来源：Renewables Now，2026-09-25）
8. 【法国】德国驻法国大使主办、法国驻德国大使馆支持的法德量子技术对话活动在巴黎举行——百余位产业、政策、初创企业及投资界高级代表出席，围绕量子产业发展、政策协调与创新合作展开深入交流。（来源：量科网，2026-09-25）
9. 【日本】东京初创公司O-ID获120万美元预种子轮融资——该公司由两名欧洲人创立，致力于打造全球首批全模块化人形机器人用于工业制造与物流，由芝加哥TAWANI Ventures领投，在日构建欧洲海外研发据点。（来源：EU Information Service，2026-09-25）
10. 【印度】印度光伏电池与组件制造商Websol Energy System在西孟加拉邦获得土地——用于建设一座4GW太阳能电池与组件制造工厂，进一步扩大印度本土光伏制造产能，响应国家太阳能制造本土化目标。（来源：PV-Tech，2026-09-25）
📋【十、国别科技政策摘要】
1. 【德国】联邦数字事务部启动“数字技术到产品”新资助计划——单项最高资助500万欧元，首批聚焦人工智能、数据生态、网络安全与云边缘计算技术，10月11日前接受申请，旨在缩短实验室成果到市场化落地周期。（来源：Startbase，2026-09-22）
2. 【中国】科技部发布国家重点研发计划“前沿卫星互联网”重点专项——2026年度项目申报指南建议并公开征求意见，由中国卫星网络集团牵头组织实施，统筹推进低轨卫星互联网系统关键技术攻关与融合应用示范。（来源：科技部，2026-09-25）
3. 【美国】哥伦比亚特区联邦上诉法院以2比1裁定人工智能国防应用——维持国防部将Anthropic列入国家安全供应链风险黑名单的决定，禁止美军及国防承包商使用Claude模型，Anthropic表示将评估后续法律救济途径。（来源：C4ISRNET，2026-09-25）
4. 【以色列】教育部与英特尔签署合作协议——将人工智能与STEM课程融入全国中小学教育体系，英特尔资深员工为师生提供导师指导与实践资源，目标推动以色列成为OECD成员国中AI教育领先者。（来源：耶路撒冷邮报，2026-09-25）
5. 【韩国】科学技术信息通信部宣布下月设立“未来开拓企划团”——统筹小型模块化反应堆、核聚变、量子、航空航天等七大SEED未来增长引擎，计划2029年实现百量子比特级国产量子计算机原型。（来源：首尔经济日报，2026-09-25）
6. 【加拿大】卡尼总理与法国总统马克龙会推动两国航天局与国防部共同开发共享航天发射场与地面接收基础设施——法国Aldoria公司已获加拿大军方合同部署太空监视数据分析平台。（来源：SpaceQ，2026-09-21）
7. 【日本】文部科学省召开第六次AI for Science推进委员会会议——启动“下一代科研基础设施建设”工作组，目标2030年共享计算资源扩至现有10倍，高被引论文中日本AI相关研究进入全球前三。（来源：中国科学报，2026-09-21）
8. 【澳大利亚】总理与内阁部发布AI基础设施建设咨询文件——探讨对前沿AI训练企业征收公共利益研究费、预留科研算力等机制，确保数据中心投资惠及本国经济，反馈截止10月9日，标志该领域取得重要进展。（来源：iStart，2026-09-23）
9. 【法国】劳工部推出“AI 2027推进”12项措施计划——新增投入8000万欧元，涵盖Explore AI免费技能测试平台、学徒AI与网络安全培训补贴、求职者AI成熟度测评及中小企业AI普及专项行动。（来源：France 24，2026-09-22）
10. 【中国】应急管理部发布“重大灾害事故风险防控与应急救援科技支撑”“十五五”国家重点研发计划——2026年度重点专项申报指南公开征求意见到9月30日截止，聚焦地震、洪水等多灾种耦合风险防控技术。（来源：西北大学科研院，2026-09-24）
💰【十一、前沿科技金融与企业动态】
1. 长沙驰芯半导体宣布完成超2亿元A+轮融资——由上海沿浦精工领投，移远通信、长沙麓山投资等产业资本跟投，资金将用于车规级安全芯片新产品流片量产与下一代产品技术迭代。（来源：科创板日报，2026-09-25）
2. 星移联信连续完成A+及A++两轮融资合计数亿元——无锡国资梁溪科创母基金、松禾创投、梅花创投等老股东追加投资，公司累计完成七轮融资，聚焦卫星互联网相控阵芯片与通信模组研发。（来源：科创板日报，2026-09-25）
3. 地瓜机器人宣布完成4亿美元C轮融资——由未来资产领投，美团战投、合肥国投、南山战新投等跟投，高瓴创投、五源资本等老股东持续加码，为近一年完成的第三轮大额融资，估值进一步攀升。（来源：中国经营报，2026-09-26）
4.合肥优艾智合机器人正式向港交所递交上市申请——冲刺“移动操作机器人第一股”，按2024年收入计为全球最大工业移动操作机器人企业，已在锂电、半导体行业实现具身智能规模落地。（来源：36氪，2026-09-26）
5. 芬兰临床阶段生物技术公司Kasvu Therapeutics完成3000万欧元A轮融资——由Hadean Ventures领投，芬兰国家基金Tesi等参投，资金将推进抗抑郁症候选药物进入临床试验。（来源：Tech Startups，2026-09-25）
6. 意大利云基础设施初创Clastix完成290万欧元种子轮融资——由意大利国家创投CDP领投，欧洲AI公司Mistral AI参投，资金用于扩展kMetal裸机Kubernetes平台研发与市场推广。（来源：Tech Startups，2026-09-25）
7. 加拿大大西洋AI公司Cohere与德国Aleph Alpha达成最终合并协议——组建估值200亿美元的跨大西洋主权AI企业，双总部设在多伦多与柏林，整合双方企业级大模型与欧洲政府客户资源。（来源：150sec，2026-09-25）
8. 数据巨头Databricks收购西雅图初创Row Zero——被收购公司开发直连企业实时数据仓库的云端电子表格，将整合至Databricks Genie智能体平台，为生成式AI提供受控实时数据访问。（来源：Unite.AI，2026-09-24）
9. 美国语音AI初创Sela完成合计2100万美元种子轮及A轮融资——专注抵押贷款销售场景的语音AI系统开发，本轮资金将用于产品功能扩展、销售团队建设与金融垂直行业市场推广。（来源：VC News Daily，2026-09-25）
10. 法律科技企业Epiq宣布收购数据泄露响应技术公司Canopy——整合网络事件响应技术与AI能力，为企业提供从威胁发现、取证分析到监管报告的全流程网络安全合规服务，加速拓展美国市场。（来源：GlobeNewswire，2026-09-25）
📊 本期统计指标数值
覆盖栏目：11 个
每日头条：1 条
TOP 12 摘要：11 条
新闻总条数：110 条
涉及国家 / 地区：中国、美国、英国、欧盟、韩国、日本、澳大利亚、德国、印度、新西兰、新加坡等
2026-09-23
·生物探索
一种治疗是否值得采用，不能只看短期指标有没有改善。给药负担、安全性、长期复发、生活质量以及适用人群，都会改变临床选择的分量。
近期的几项研究覆盖随机试验、前瞻性队列、注册研究、人胰岛细胞实验与机器学习验证。共同的问题是：当证据被放回具体人群和时间尺度，哪些结论足以支持行动，哪些仍只能用于判断风险或提出下一步假设？
01 · 青少年HIV｜长效注射｜随机试验每八周注射一次，能否比每日口服更稳地维持病毒抑制？
在已稳定抑制病毒的非洲青少年中，长效注射减少了病毒学失败，但结论仅适用于严格筛选的人群。
该研究在肯尼亚、南非、乌干达和津巴布韦5家诊所纳入476名12岁至不足20岁的HIV感染青少年，均已持续病毒学抑制超过12个月且无既往治疗失败，随机接受每8周长效注射或每日口服治疗，随访96周主要结局。
截至96周，长效注射组与口服组分别有2人和15人出现连续两次病毒载量不低于50copies/mL，估计比例为0.9%和6.4%。长效方案达到非劣效并显示优效，但严重不良事件比较无统计学差异。结果说明，对长期稳定抑制且能按时注射的青少年，降低每日服药负担并未牺牲病毒控制。
关键数据
共随机476人：长效注射235人，口服治疗241人
96周确认病毒载量≥50 copies/mL：0.9%比6.4%
组间估计差异为-5.5%，99%CI -10.3%至-1.5%
严重不良事件风险比1.16，95%CI 0.54至2.51
这项研究值得关注的地方
为撒哈拉以南非洲青少年从每日口服转向长效注射提供了直接随机证据。
注：
开放标签试验；参与者均已长期病毒学抑制、无既往治疗失败，且98%为垂直感染，不能外推至未抑制、治疗失败或其他HIV人群。
02 · 宫内节育器｜操作疼痛｜局部麻醉放置宫内节育器前注入局麻药，疼痛能降低多少？
对未生育女性，术前宫腔注入甲哌卡因降低了放置疼痛，也让更多人认为疼痛可以耐受。
该研究在瑞典11家门诊纳入370名18至31岁、未生育且选择较小直径置入管宫内节育器的参与者，双盲随机分为两组，各185人；放置前2分钟分别宫腔注入10mL甲哌卡因或生理盐水。
置入时平均疼痛评分由安慰剂组的58.6mm降至甲哌卡因组的43.8mm，平均差14.8mm；按临床医生校正后结果相近。认为疼痛可耐受者分别占98.3%和91.4%，对应NNT为15。由此可见，这一局部处理不仅改变疼痛评分，也改善了患者对操作的可接受程度。
关键数据
平均疼痛评分：43.8 mm比58.6 mm
平均差14.8 mm，95%CI 10.0至19.6
可耐受疼痛比例：98.3%比91.4%
NNT为15，95%CI 9至43
这项研究值得关注的地方
提供了一个操作前即可实施、并同时改善疼痛与耐受性的随机对照方案。
注：
研究限于18至31岁未生育者及较小直径置入管，不能直接外推至经产者、其他器械或不同临床流程。
03 · 蛇伤｜辅助治疗｜Ⅱ期试验抗蛇毒血清之后再加药，为何没有改善主要结局？
住院蛇伤患者在抗蛇毒血清后较晚接受varespladib，神经毒性和蝰蛇毒性主要结局均未改善。
该研究在印度和美国开展多中心、双盲、安慰剂对照Ⅱ期试验，140名蛇毒中毒患者随机接受varespladib或安慰剂，均同时接受包括抗蛇毒血清在内的标准治疗；139人进入分析，其中用药组73人、安慰剂组66人。
研究药物平均在咬伤后7.3小时、抗蛇毒血清后3.3小时启动。眼镜蛇科咬伤患者恢复持续抬头5秒的平均时间为27.6小时和36.2小时，但差异不显著；蝰蛇咬伤患者14天严重度评分曲线下面积为660和629，同样未见差异。结果提示，当前给药时点和混合蛇种条件下，辅助治疗未达到预设目标。
关键数据
随机140人，139人纳入分析
平均在咬伤后7.3小时开始研究药物
眼镜蛇科患者抬头恢复时间：27.6小时比36.2小时，p=0.6
蝰蛇患者14天评分曲线下面积：660比629，p=0.7
这项研究值得关注的地方
阴性结果明确了后续研究需要重点检验的变量：给药时间、蛇种和毒液表型。
注：
Ⅱ期样本量有限，蛇种、毒液组成、临床表现及抗蛇毒血清治疗存在异质性；结果不能排除更早给药或特定蛇种中的效果。
04 · 心肌梗死｜血糖谱｜预后分层未达到糖尿病诊断线，心梗后的风险是否已经上升？
心梗后血糖异常与不良结局风险呈梯度关联，风险信号并不限于已确诊糖尿病患者。
该研究利用瑞典SWEDEHEART注册资料，回顾性纳入2006至2017年参加心脏康复且有血糖信息的47558名成年心肌梗死患者，按血糖状态、空腹血糖和糖化血红蛋白评估后续心血管结局，中位随访4.7年。
随访期间共有9321人发生全因死亡、再次心肌梗死或缺血性卒中的复合结局。与血糖正常者相比，糖尿病前期、可能糖尿病、新发糖尿病和已知糖尿病的风险比依次为1.07、1.22、1.22和1.73。空腹血糖与结局近似线性相关，而糖化血红蛋白的预测信息主要见于已确诊糖尿病者，提示风险识别不应只依赖诊断标签。
关键数据
纳入47558名心肌梗死后患者
中位随访4.7年，发生9321例主要不良心血管事件
糖尿病前期风险比1.07，已知糖尿病风险比1.73
空腹血糖与结局呈近似线性关联
这项研究值得关注的地方
将心梗后的血糖评估从“是否患糖尿病”推进到连续风险谱，有助于识别诊断阈值以下的高风险者。
注：
回顾性观察研究只能支持关联和预测，不能证明血糖升高导致结局；对象为参加心脏康复且有血糖资料的瑞典患者。
05 · 人胰岛｜β细胞｜药物靶点同为DYRK1A抑制剂，为何只有部分药物增强β细胞身份？
人胰岛实验发现，促进β细胞增殖并不等于维持其功能身份，不同DYRK1A抑制剂不能互换。
该研究在人供体胰岛中比较harmine、2-2c、5-IT、INDY、leucettine、CC-401和GNF4877七种小分子，结合基因表达、单细胞RNA测序、增殖、免疫细胞化学及蛋白质组学，区分β细胞增殖与身份标志增强所依赖的通路。
七种抑制剂均通过抑制DYRK1A促进人β细胞增殖，但沉默DYRK1A并未改变β细胞转录因子和身份标志。只有harmine、2-2c和5-IT增强这些表型标志，另外四种未呈现同样效果。实验进一步将harmine的身份增强作用关联到PKA通路激活，但相应“第二靶点”仍未确定，提示筛选候选药物时需同时考察细胞数量与功能身份。
关键数据
共比较7种DYRK1A小分子抑制剂
7种均促进人β细胞增殖
3种增强β细胞身份标志，另4种未增强
DYRK1A沉默未影响相关转录因子和身份标志
这项研究值得关注的地方
拆分了“促增殖”与“维持身份”两类药效，为β细胞再生候选物的评价提供更精细框架。
注：
证据来自人胰岛离体实验及相关分析；第二靶点尚未确定，不能据此判断人体疗效、安全性或糖尿病逆转效果。
06 · 早期食管癌｜内镜切除｜长期复发浅层浸润食管癌切除后，哪些患者或可先随访？
内镜切除后的浅层浸润食管癌总体生存良好，但转移和第二原发癌风险因病理类型而不同。
该研究前瞻性纳入385名内镜切除后诊断为黏膜肌层或浅表黏膜下层浸润食管癌的患者，包括315例鳞状细胞癌和70例腺癌，评估总生存、转移复发、局部复发及第二原发食管癌。
鳞癌和腺癌5年总生存率分别为92.3%和94.2%。在淋巴血管侵犯阴性且未追加治疗者中，两类肿瘤5年生存率仍为94.0%和93.3%。不过，鳞癌患者5年第二原发食管癌累积发生率达25.8%；在淋巴血管侵犯阴性鳞癌中，≤30mm的0-II型病灶转移复发率为2.9%。这些结果支持基于病理与病灶特征分层，而非一概追加治疗。
关键数据
共385人：鳞癌315例，腺癌70例5年
总生存率：鳞癌92.3%，腺癌94.2%
淋巴血管侵犯阴性且未追加治疗者5年生存率：94.0%和93.3%5年
第二原发食管癌累积发生率：鳞癌25.8%，腺癌3.6%
这项研究值得关注的地方
以长期前瞻性数据细化了内镜切除后监测与追加治疗之间的风险权衡。
注：
这是队列研究而非监测与追加治疗的随机比较；部分亚组置信区间较宽，低风险特征不能等同于零转移风险。
07 · 克罗恩病｜肠结核｜机器学习手机模型能否分清克罗恩病与肠结核这对“临床近邻”？
同一中心前瞻性验证中，手机端模型较参考方法更准确地区分克罗恩病与肠结核，但仍需外部检验。
该研究使用印度一家三级中心1066名患者的数据库训练机器学习模型，其中克罗恩病650例、肠结核416例，输入30项临床、内镜和影像变量；表现最佳的CatBoost模型被整合进手机应用，并在同一中心121人中前瞻性验证。
十次内部交叉验证的平均AUROC为0.886，敏感度76.0%、特异度84.1%。前瞻队列AUROC升至0.921，高于贝叶斯参考标准的0.750；最佳阈值下敏感度和特异度分别为86.4%和85.5%。症状持续时间、横行溃疡、肉芽肿、直乙结肠受累和肛周病变是主要预测变量，说明常规信息可被组合为即时鉴别工具。
关键数据
训练数据库1066人，前瞻验证121人
内部交叉验证平均AUROC 0.886
前瞻验证AUROC 0.921，参考标准为0.750
最佳阈值下敏感度86.4%、特异度85.5%
这项研究值得关注的地方
把复杂鉴别诊断转化为床旁可用的预测工具，针对结核流行地区的真实临床难题。
注：
训练和前瞻验证均来自同一中心；模型表现属于诊断预测证据，不能证明应用后会减少误诊或改善患者结局。
08 · 前交叉韧带｜十年随访｜移植物选择前交叉韧带重建十年后，移植物差异体现在哪里？
三种重建方式的十年生活质量相近，但再损伤和影像学骨关节炎呈现不同取舍。
该研究将330名前交叉韧带损伤患者随机分配至髌腱、单束腘绳肌腱或双束腘绳肌腱重建，每组110人；分别在基线及术后2、5、10年评估生活质量、临床表现、再损伤与影像学骨关节炎，287人完成十年随访。
十年时三组ACL生活质量评分分别为76.4、77.7和77.3，差异不显著。髌腱组创伤性再损伤较少，为8%，另两组为22%和21%；但其外侧间室骨关节炎更多，为42%，另两组均为23%。总体45%出现影像学骨关节炎，且内侧或外侧骨关节炎患者生活质量较低。长期选择因此不是单一“最佳移植物”，而是稳定性与影像改变之间的权衡。
关键数据
330人随机分组，287人完成十年随访
十年生活质量评分：76.4、77.7和77.3，p=0.912
创伤性再损伤：8%、22%和21%
十年影像学骨关节炎比例为45%
这项研究值得关注的地方
十年随机随访同时呈现患者体验、再损伤和结构改变，避免仅凭短期稳定性选择移植物。
注：
十年完成率为87%，部分长期结局可能受失访和后续治疗影响；研究者强调所观察到的关联效应量均较小。
值得关注的趋势
01｜疗效正在从单一终点转向真实治疗负担
长效HIV治疗和宫内节育器镇痛试验表明，病毒控制、疼痛之外，给药频率与操作耐受性也能成为影响选择的实质结局，但必须在具体适用人群中解释。
02｜分层比统一阈值更接近临床决策
心梗后血糖谱、内镜切除后食管癌及韧带重建十年结局都显示，诊断标签或平均效果不足以覆盖风险差异；连续指标、病理特征和长期结构结局需要共同进入判断。
03｜工具与机制离临床改变仍有一段验证距离
人胰岛实验揭示同类抑制剂并不等效，机器学习模型展示了较高鉴别能力；但前者仍是离体机制证据，后者尚缺跨中心验证及患者结局研究，均不能直接等同于临床获益。
参考文献
1. Bwakura-Dangarembizi M, Chappell E, Kityo C, Anena DL, Kiilu C, Archary M, Jafta L, Mujuru HA, Nakabuye S, Akabwai GP, Siika A, Mngqibisa R, Mugerwa H, Walker S, Seeley J, Burger D, Omar A, South A, Nguyen H, Giaquinto C, Spittle B, Bamford A, Kekitiinwa AR, Ford D, Pett S; LATA trial team. Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial. Lancet. 2026 Sep 17:S0140-6736(26)01537-0.
PubMed：https://pubmed.ncbi.nlm.nih.gov/42753775/
DOI：https://doi.org/10.1016/S0140-6736(26)01537-0
2. Elgemark K, Envall N, Kopp Kallner H. Intrauterine Mepivacaine Instillation vs Placebo for Pain During IUD Placement: A Randomized Clinical Trial. JAMA. 2026 Sep 17:e2614217.
PubMed：https://pubmed.ncbi.nlm.nih.gov/42752558/
DOI：https://doi.org/10.1001/jama.2026.14217
3. Gerardo CJ, Bhalla A, Mohanty CR, Sahu BK, Kumar S, Agrawal S, Ayyan S M, Shu E, Deuson T, Kumar R M, Beatty NL, Akpunonu PD, Shirazi FM, Watkins S, Ruha AM, Varney SM, Goel AK, Gautam M, Arnold J, Bammigatti C, Francis SJ, Selvam S, Kumar H, Aizenberg A, Micciche A, Bledsoe RS, Boatright G, Oomman SC, Samuel SP, Wittes JT, Carter RW, Lewin MR, Platts-Mills TF. Adjunctive Varespladib after antivenom administration for snakebite: A phase II randomized clinical trial. PLoS Negl Trop Dis. 2026 Sep 21;20(9):e0014736.
PubMed：https://pubmed.ncbi.nlm.nih.gov/42766697/
DOI：https://doi.org/10.1371/journal.pntd.0014736
4. Haider A, Hagström E, Ishak D, Hadziosmanovic N, Norhammar A, Velders M, Batra G. Diabetes status, fasting glucose and HbA1c, and outcomes after myocardial infarction: a retrospective registry-based Swedish cohort study. BMJ Open. 2026 Sep 18;16(9):e121970.
PubMed：https://pubmed.ncbi.nlm.nih.gov/42760071/
DOI：https://doi.org/10.1136/bmjopen-2026-121970
5. Wang P, Kumar K, Lambertini L, Liu H, Wood O, Chen S, Pillard A, Scott DK, Paulo JA, Gygi SP, Khamrui S, Mueller S, Garcia-Ocana A, Karakose E, Lazarus MB, DeVita RJ, Stewart AF. Harmine selectively enhances human beta cell identity markers and function via protein kinase A pathways. Diabetologia. 2026 Sep 21.
PubMed：https://pubmed.ncbi.nlm.nih.gov/42766004/
DOI：https://doi.org/10.1007/s00125-026-06857-5
6. Ishihara R, Takahashi H, Abe S, Yoshio T, Yano T, Suzuki Y, Matsueda K, Ono Y, Yamamoto Y, Ono H, Kawata N, Hatta W, Takahashi A, Oda I, Amano Y, Ishikawa H, Oyama T. Long-term Outcomes After Endoscopic Resection for pMM/SM1 Esophageal Cancer: A Multicenter Prospective Cohort Study. Am J Gastroenterol. 2026 Sep 18.
PubMed：https://pubmed.ncbi.nlm.nih.gov/42754974/
DOI：https://doi.org/10.14309/ajg.0000000000004209
7. Mohta S, Kutum R, Dhoundiyal A, Pendyala R, Dev H, Kante B, Vuyyuru SK, Kumar P, Narang H, Mahajan M, Virmani S, Kumar M, Bahl S, Jayswal N, Das P, Sharma R, Makharia G, Chaudhury S, Kedia S, Sethi T, Holani R, Ahuja V. Development and Prospective Validation of a Machine Learning-Based Mobile Application (CROHN'S AID) for Differentiating Crohn's Disease From Intestinal Tuberculosis in Tuberculosis-Endemic Regions. Aliment Pharmacol Ther. 2026 Sep 21.
PubMed：https://pubmed.ncbi.nlm.nih.gov/42768418/
DOI：https://doi.org/10.1111/apt.70984
8. Mohtadi N, Chan D, Hunter D, Bertiche P, Marmura H, Bryant D. Quality-of-life outcomes and osteoarthritis development at 10-years after anterior cruciate ligament reconstruction: A large randomized clinical trial comparing patellar tendon, hamstring tendon and double-bundle grafts. J ISAKOS. 2026 Sep 19:101220.
PubMed：https://pubmed.ncbi.nlm.nih.gov/42762953/
DOI：https://doi.org/10.1016/j.jisako.2026.101220
责编|探索君
排版|探索君
转载请注明来源于【生物探索】
声明：本文仅用于分享，不代表平台立场，如涉及版权等问题，请尽快联系我们，我们第一时间更正，谢谢！
End
2026-09-22
·微信
Clinical Infectious Diseases Volume 82 Issue 1
临床传染病学 82卷1期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病学技艺）
1
Peasants' Revolt, 1381
1381年农民起义
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692
In the Literature（文献概览）
2
In the Literature
文献概览
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631
State-of-the-Art Review（最新技术综述）
3
State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis
最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗
Prathit A Kulkarni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483
Clinical Dilemmas in Infectious Diseases（传染病临床难题）
4
“Insisting on Treatment”
“坚持治疗”
Kevin Andrew Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282
Voices of ID（传染病之声）
5
Martin Arrowsmith and Me
马丁·阿罗史密斯与我
Janet R Gilsdorf
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277
Invited Commentary（特邀述评）
6
The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions
2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题
Lao-Tzu Allan-Blitz and Kenneth H Mayer
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567
Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控）
7
Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings
资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模
Joshua M Chevalier and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236
8
The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort
巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播
Leandro S Garcia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794
9
Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission
超越诊断：Xpert循环阈值作为结核病传播的预测指标
Lauren Linde and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791
10
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告
Ava J Dorazio and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638
Clinical Practice and Policy（临床实践与政策）
11
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis
痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析
Charl Bezuidenhout and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389
12
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题
Matthew R Davis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250
13
Home Testing for Contagious Illness: Historical Context and Modern Caveats
传染性疾病居家检测：历史背景与现代注意事项
Abigail Zuger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623
Fungal Infections（真菌感染）
14
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial
评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验
Morris K Rutakingirwa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432
15
Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals
美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联
Thomas P Lodise and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472
16
Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data
美国隐球菌病导致的死亡率分析：基于死亡证明数据
Thomas J Walsh and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
17
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
晚期艾滋病患者危重症结局：30年的双国数据
Bryan Tan and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362
18
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357
Babafemi O Taiwo and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375
19
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果
Nadège Néant and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385
20
Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?
长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？
Catia Marzolini
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386
21
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study
多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果
Maria Ines Figueroa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415
22
DOLCE: Sweet Success for Dolutegravir/Lamivudine?
DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？
Laura J Waters
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
23
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响
Alexander J Sundermann and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216
24
Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions
两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施
Nicholas F Angelino and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330
Photo Quiz（影像问答）
25
The Clue That Wriggled into View
蜿蜒入目的线索
Nitin Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
26
Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection
比较生成式人工智能与专家在导管相关尿路感染检测中的应用
Shatha Alshanqeeti and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486
Sexually Transmitted Infections（性传播感染）
27
Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis
不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析
Arthur Wong and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401
Photo Quiz（影像问答）
28
A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure
一例46岁患者持续出现意识状态改变伴呼吸衰竭
Ann F Yang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439
Sexually Transmitted Infections（性传播感染）
29
Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort
HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素
Michalina Montaño and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464
30
Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York
开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者
Caroline E Mullis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109
31
Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections
为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药
Julia C Dombrowski and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527
Bacterial Infections（细菌性感染）
32
Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil
巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究
Sun Kim and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206
33
Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022
脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测
Stephen A Clark and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274
34
Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses
与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性
Fergus Hamilton and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
35
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究
Anca Streinu-Cercel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406
36
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗
Wuyan Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548
Emerging Infections(新兴感染)
37
“I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies
“疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作
Diana Valencia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179
38
Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024
2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施
Alessandra Løchen and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420
39
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值
Ruxandra Draghia-Akli and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
40
Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative
在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议
Allan M Seibert and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434
41
Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada
美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率
Sally B Coburn and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446
42
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果
Kunjal Patel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538
43
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
Win比值与REPRIEVE研究的主要发现一致并增强了其解释性
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477
44
The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States
临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510
Mycobacterial Infections（分枝杆菌感染）
45
Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts
结核密切接触者中体重指数与新发结核病的关系
María B Arriaga and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475
46
The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study
青年在家庭内结核病传播中的作用：一项家庭接触队列研究
Meredith B Brooks and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490
47
Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa
南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析
Alexandra de Nooy and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495
48
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示
Daniel J Grint and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527
49
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性
Khalid M Dousa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
50
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine
一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性
Peyman Banooni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033
51
Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用
Grace Montepiedra and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198
52
Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood
青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较
Makoto Saito and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552
53
Why Did the Antimalarial Drug Cross the Placenta?
抗疟药为何要穿过胎盘？
Stephen J Rogerson and Holger W Unger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553
Viral Infections（病毒性传染病）
54
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素
Jennifer Audsley and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281
55
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病
Lauren A Powers and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285
Correspondence（读者来信）
56
Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality
揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493
57
Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations
对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494
58
Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need
文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究
Carl Boodman and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518
59
Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection
宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱
Sarwat Khalil and M Rizwan Sohail
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519
60
It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections
是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了
Alberto Enrico Maraolo and Giancarlo Ceccarelli
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533
61
Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB)
实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了
Jason M Pogue and Keith S Kaye
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534
62
COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias?
COVID-19和细菌性肺炎：保护作用还是诊断偏差？
Duygu Aydın and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539
63
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究
John C Hu and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540
64
Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection
长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路
Beatrice Barda and Marco Bongiovanni
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482
65
Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings
超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制
Schawanya Kaewpitoon Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535
66
Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases
重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差
Shiuan-Chih Chen and Chun-Chieh Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536
67
Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis
血培养肉汤宏基因组测序用于诊断苛养性心内膜炎
Po-Hsiu Huang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554
Corrections（更正）
68
Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572
69
Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa
《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711
Clinical Infectious Diseases Volume 82 Issue Supplement_1
临床传染病学 82卷 增刊1期
https://academic.oup.com/cid/issue/82/Supplement_1
SUPPLEMENT（增刊）
Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence
实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述
SUPPLEMENT ARTICLES（增刊论著）
1
Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述
Amanda C Smith and Ellen N Kersh
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665
2
Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods
沙眼衣原体培养、活性检测及测序方法的叙述性综述
Alana K Sterkel and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697
3
Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods
淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述
Olusegun O Soge and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698
4
Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae
实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述
Megan Crumpler and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696
5
Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae
淋病奈瑟菌抗菌药物耐药性检测方法综述
Kara K Mitchell and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706
6
Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature
沙眼衣原体和淋病奈瑟菌即时检测技术文献综述
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699
Clinical Infectious Diseases Volume 82 Issue 2
临床传染病学 82卷 2期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Interior of the Old Jersey Prison Ship in the Revolutionary War
美国革命战争中老泽西监狱船的内部景象
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011
IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论）
3
2025 Content Collections from the IDSA Journals
IDSA期刊2025年内容合集
Roger Bedimo and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041
State-of-the-Art Review（前沿综述）
4
State-of-the-Art Review: Chagas Disease—an Enduring Challenge
前沿综述：恰加斯病——一个持续存在的挑战
Nelson Iván Agudelo Higuita and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654
IDSA Features（美国传染病学会特色内容）
5
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件
Julia L Marcus and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648
Voices of ID（传染病之声）
6
A “Terminal Infection”
“绝症感染”
Jennifer Furin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332
Invited Commentary（特邀评论）
7
A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail
区分病毒与细菌感染的快速检测：寻找“圣杯”
Lao-Tzu Allan-Blitz and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585
Bacterial Infections（细菌感染）
8
Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort
脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验
Emilie Marie Eriksen and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304
9
What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？
Linda Bussini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323
10
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析
Francesc Escrihuela-Vidal and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
11
Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons
在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学
Thomas Drumel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430
12
Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis
中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析
Lukun Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466
13
Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1
HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果
Marc Wirden and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422
14
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法
Cameron T Nutt and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444
Mycobacterial Infections（结核分枝杆菌感染）
15
Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting
刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析
Bertin C Bisimwa and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451
16
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country
生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验
Sandra Pérez-Recio and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491
17
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
减少家庭内结核病传播：一项试点整群随机对照试验
Cinthya Ruiz-Tagle and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526
18
(Un)masking Tuberculosis
（揭开）结核病的“面具”
Joseph N Burzynski and Neil W Schluger
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528
19
Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)
评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM）
Lucía CarratalàCastro and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525
Sexually Transmitted Infections（性传播感染）
20
Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections
多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响
Michael W Traeger and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488
21
Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
填补空白：多西环素预防细菌性性传播感染的最新进展
Aniruddha Hazra and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062
22
Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022
2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现
Sarah B Wondmeneh and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015
Viral Infections（病毒性感染）
23
Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling
通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用
Sithembiso Velaphi and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098
Photo Quiz（影像问答）
24
Bursting at the Seams
“撑破”
Maxwell Olenski and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488
Viral Infections（病毒性感染）
25
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021
2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查
Nayab Mehmood and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151
26
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication
灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分
Konstantin Chumakov and Stanley A Plotkin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215
Photo Quiz（影像问答）
27
Intracranial Lesion in a Patient With Chronic Myeloid Leukemia
慢性髓性白血病患者颅内病变
Mohammed Shakeel Sillat and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441
Viral Infections（病毒性感染）
28
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020
在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据
Justin Z Amarin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194
29
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection
一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注
Astrid Wintering and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125
Clinical Trials（临床实验）
30
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验
Michelle K Yong and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409
31
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8
一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验
Paul T Scott and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604
32
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial
直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验
David C Gaston and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677
33
The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship
对完美诊断检测的诱人追求：平衡创新与管理
K C Coffey and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674
Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病）
34
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白
Rebecca Crowder and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
35
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估
Steven K Grinspoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542
36
REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks
HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少
Matthew S Durstenfeld
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543
37
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究）
Sergio Serrano-Villar and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565
38
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
丙酚替诺福韦与体重：我们最终是否打破了平衡？
John R Koethe
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566
39
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study
在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局
Gbolahan Ajibola and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568
40
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
2015-2023年美国开具HIV暴露后预防处方的患者趋势
John N Le and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581
Immunocompromised Hosts（免疫功能低下宿主）
41
Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen
根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后
Anne-Sophie Brunel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134
42
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响
Genovefa A Papanicolaou and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646
43
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients
在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用
Ajit P Limaye and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632
44
The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined
来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定
Yoichiro Natori and Martina Sester
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633
45
IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes
北美出现的IL12RB1缺陷：拓展临床表型
Chen Wang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637
Vaccines（疫苗）
46
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究
Raquel Ron and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435
47
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性
Omid Rezahosseini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455
48
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应
Audrey Godin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484
49
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果
Sara Y Tartof and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496
Sexually Transmitted Infections（性传播感染）
50
Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID)
生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析
Kay Htaik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295
51
Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022
2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况
Guoyu Tao and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314
52
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析
Meredith E Clement and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572
Viral Infections（病毒性感染）
53
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus
对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析
Paulina Sudnik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310
54
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines
处于危急状况：迫切需要支持猴痘治疗和诊断管线
Carmen Perez Casas and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529
Correspondence（读者来信）
55
Caution in Interpreting INSTIs and Weight in Observational Studies
在观察性研究中解读整合酶抑制剂与体重关系时需谨慎
Esteban Martínez
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569
56
Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort
整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570
57
Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens
现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加
Xinsheng Wu and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571
58
C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?
结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？
Patrick K Moonan and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575
59
C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care
结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物
Lillian Tugume and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576
60
The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial
胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587
61
Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture
效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588
62
Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis?
口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598
63
Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis
朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进
Romane Pouy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599
64
Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use
利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用
James S Ford and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601
65
Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions
平衡人工智能创新与实用的败血症定义
Chanu Rhee and Michael Klompas
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602
66
Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies
生物疗法中结核病的精准预防：筛查策略之外的启示
Shiuan-Chih Chen and Yuan-Ti Lee
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559
67
Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps
重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训
Nathkapach K Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605
Clinical Infectious Diseases Volume 82 Issue 3
临床传染病学 82卷 3期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Dracunculiasis, 1674
1674年的麦地那龙线虫病
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page i, https://doi.org/10.1093/cid/ciag089
In the Literature（文献聚焦）
2
In the Literature
文献聚焦
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag012
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Managing Vulvovaginal Candidiasis
前沿综述：外阴阴道念珠菌病的治疗
Riina Rautemaa-Richardson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 371–382, https://doi.org/10.1093/cid/ciaf673
Ethics Rounds（伦理探讨）
4
CARB Your Enthusiasm: An Ethics-Informed Analysis for Clinicians of the US National Action Plan for Combating Antibiotic-Resistant Bacteria
谨慎对待抗生素：基于伦理学分析美国国家抗耐药菌行动计划对临床医生的启示
Hunter Jackson Smith and Chelsea Modlin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 383–388, https://doi.org/10.1093/cid/ciaf478
Voices of ID（传染病之声）
5
Mothers
母亲们
Maria Koshy
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 389–390, https://doi.org/10.1093/cid/ciaf338
Bacterial Infections（细菌性感染）
6
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
多粘菌素与美罗培南联合治疗对碳青霉烯类耐药革兰氏阴性菌所致肺炎或血行感染患者预后的影响
Mariya Huralska and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 391–398, https://doi.org/10.1093/cid/ciaf398
7
We Cannot Overcome the Mediocrity of Colistin
我们无法忽视多粘菌素的平庸疗效
Jason C Gallagher
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 399–401, https://doi.org/10.1093/cid/ciaf592
8
Comparing Clinical, Microbiological, and Genetic Definitions of Relapse in Patients With Subsequent Episodes of Methicillin-resistant Staphylococcus aureus Bone and Joint Infection
比较耐甲氧西林金黄色葡萄球菌骨关节感染后续发作患者复发在临床、微生物学和遗传学上的定义
Kevin Bouiller and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 402–410, https://doi.org/10.1093/cid/ciaf448
9
Non-Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia, and Acinetobacter baumannii
新型β-内酰胺/β-内酰胺酶抑制剂对非肺炎克雷伯菌碳青霉烯酶的抗菌特性，第二部分：洋葱伯克霍尔德菌复合群、嗜麦芽窄食单胞菌和鲍曼不动杆菌
Andrew J Fratoni and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 411–419, https://doi.org/10.1093/cid/ciaf403
Clinical Trials（临床试验）
10
Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
炎症性风湿性疾病患者感染期间继续使用与暂时停用免疫调节剂的随机对照试验
Merel A A Opdam and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 420–426, https://doi.org/10.1093/cid/ciaf442
11
Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial)
泰国疑似肺结核患者中雾化支气管扩张剂增强痰诱导的有效性：一项随机对照试验（NeB-TB试验）
Pichanon Mingchay and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 427–435, https://doi.org/10.1093/cid/ciaf580
12
Bone Biopsy not Superior to Ulcer Bed Biopsy–guided Antibacterial Therapy on Remission of Diabetic Foot Osteomyelitis: A Randomized Controlled Trial
在指导用于缓解糖尿病足骨髓炎的抗菌治疗方面骨活检并不优于溃疡床活检：一项随机对照试验
Rimke S Lagrand and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 436–442, https://doi.org/10.1093/cid/ciaf684
13
Do We Need a Bone Biopsy for Managing Diabetic Foot Osteomyelitis?
我们是否需要对糖尿病足骨髓炎进行骨活检？
Eric M Senneville and Benjamin A Lipsky
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 443–445, https://doi.org/10.1093/cid/ciaf685
Critical Care and Sepsis（重症监护与败血症）
14
Contamination of Blood Cultures Drawn From Arterial Catheters Versus Venipuncture or Venous Catheters in Critically Ill Patients: A Systematic Review and Meta-analysis
危重患者从动脉导管与静脉穿刺或静脉导管采集血培养的污染情况：一项系统综述和荟萃分析
Takatoshi Koroki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 446–452, https://doi.org/10.1093/cid/ciaf260
15
Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis Trial
重新评估降钙素原指导的败血症危重患者抗生素治疗：来自ADAPT-败血症试验的启示
Simran Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 453–458, https://doi.org/10.1093/cid/ciaf336
Infection Control and Hospital Epidemiology（传染病控制与医院流行病学）
16
Effectiveness and Safety of Methods to Prevent Bloodstream and Other Infections and Noninfectious Complications Associated With Peripherally Inserted Central Catheters: A Systematic Review and Meta-Analysis
预防经外周静脉置入中心静脉导管相关血行感染及其他感染和非感染性并发症的方法的有效性和安全性：一项系统综述和荟萃分析
Andreea Dobrescu and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 459–472, https://doi.org/10.1093/cid/ciaf063
17
Using Generative Artificial Intelligence for Healthcare-Associated Infection Surveillance
利用生成式人工智能进行医院感染监测
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 473–479, https://doi.org/10.1093/cid/ciaf619
18
Artificial Intelligence and the Future of Healthcare-Associated Infection Surveillance: Bridging Precision, Partnership, Practice, and People
人工智能与医院感染监测的未来：融合精准、合作、实践与人文
Mamdooh Alzyood
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 480–483, https://doi.org/10.1093/cid/ciaf620
Infections in Older Adults（老年传染病学）
19
Evaluation of Influenza Antiviral Prophylaxis for Long-term Care Residents: A Systematic Review and Meta-Analysis
长期护理机构居民流感抗病毒预防的效果评价：一项系统综述和荟萃分析
Ryan Hanula and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 484–493, https://doi.org/10.1093/cid/ciaf101
20
Implementation of Diagnostic Stewardship to Improve Urinary Tract Infection Antibiotic Use Across 3 Medical Centers
在三家医疗中心实施诊断管理以改善尿路感染抗生素的使用
Kimberly C Claeys and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 494–500, https://doi.org/10.1093/cid/ciaf411
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
21
Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis
儿童结核病一线治疗的不良反应：一项系统综述和荟萃分析
Michael Prodanuk and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 501–512, https://doi.org/10.1093/cid/ciaf152
22
The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016–2022
妊娠对结核病治疗效果的影响：基于2016-2022年巴西国家监测数据的分析
Silvia S Chiang and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 513–521, https://doi.org/10.1093/cid/ciaf233
Photo Quiz（影像问答）
23
Persistent Fever and Back Pain After Liver Transplantation
肝移植后持续发热和背痛
Toshiyuki Kishida and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 522–525, https://doi.org/10.1093/cid/ciaf489
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
24
Stool Processing Methods for Xpert Ultra Testing in Childhood Tuberculosis: A Prospective, Multicountry Accuracy Study
儿童结核病Xpert Ultra检测的粪便处理方法：一项前瞻性、多国准确性研究
Devan Jaganath and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 526–534, https://doi.org/10.1093/cid/ciaf289
Photo Quiz（影像问答）
25
A Bloom Beneath the Skin
皮下绽放之花
Yi Rong Chew and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 535–538, https://doi.org/10.1093/cid/ciaf550
Vector-Borne Diseases（虫媒传染病）
26
Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data, and Outcomes
过去十年无形体病趋势：临床特征、实验室数据和预后回顾
Silpita Katragadda and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 539–547, https://doi.org/10.1093/cid/ciaf171
27
Completion of Paired Serological Testing Algorithms for Spotted Fever Rickettsiosis and Ehrlichiosis, North Carolina: 2017–2020
斑点热立克次体病和埃里希体病配对血清学检测算法的完成情况，北卡罗来纳州：2017-2020年
Huipeng Liao and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 548–555, https://doi.org/10.1093/cid/ciaf176
COVID-19/SARS-COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Effect of Metformin on the Risk of Post-COVID-19 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study
二甲双胍对超重或肥胖人群患新冠后综合征风险的影响：一项基于人群的回顾性队列研究
Ubonphan Chaichana and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e423–e432, https://doi.org/10.1093/cid/ciaf429
29
Preventing Long COVID With Metformin
使用二甲双胍预防新冠长期症状
Carolyn T Bramante and David R Boulware
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e433–e435, https://doi.org/10.1093/cid/ciaf700
30
Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods
COVID-19疫苗接种和既往感染在奥密克戎变异株出现前及奥密克戎时期降低新冠长期症状风险的有效性
Sara Carazo and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e436–e445, https://doi.org/10.1093/cid/ciaf549
31
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness
国际合作制定并统一新冠期间奈玛特韦/利托那韦药物相互作用指南：为未来大流行准备汲取的经验教训
Safia Kuriakose and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e446–e454, https://doi.org/10.1093/cid/ciaf606
Endovascular Infections（血管内感染）
32
Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study
念珠菌感染性心内膜炎的抗真菌治疗：一项全国队列研究中棘白菌素与其他治疗方案比较
Siri Kurland and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e455–e461, https://doi.org/10.1093/cid/ciaf312
33
Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study
我们是否应延长感染性心内膜炎口服抗生素的使用？ENDO-ORAL研究
Benoit Rallet and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e462–e470, https://doi.org/10.1093/cid/ciaf452
34
Rethinking the Routine: Are Repeat Blood Cultures Necessary After Completion of Infective Endocarditis Treatment?
重新思考常规做法：感染性心内膜炎治疗完成后是否需要重复血培养？
Jean Regina and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e471–e474, https://doi.org/10.1093/cid/ciaf617
35
Posttreatment Blood Cultures in Patients With Infective Endocarditis: Valuable, Inconsequential, or Worse?
感染性心内膜炎患者治疗后的血培养：有价值、无关紧要还是有害？
Daniel C DeSimone and Larry M Baddour
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e475–e476, https://doi.org/10.1093/cid/ciaf618
Fungal Infections（真菌感染）
36
Fungal Meningitis in US Patients Who Received Epidural Anesthesia in Matamoros, Mexico
在墨西哥马塔莫罗斯接受硬膜外麻醉的美国患者中的真菌性脑膜炎
Dallas J Smith and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e477–e484, https://doi.org/10.1093/cid/ciaf399
37
Empirical Antifungal Treatment of Critically ⅢPatients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
流感相关急性呼吸窘迫综合征危重患者的经验性抗真菌治疗：一项倾向评分加权观察性研究
Stefan Hatzl and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e485–e493, https://doi.org/10.1093/cid/ciaf507
38
Is Empirical Antifungal Therapy the Next Path Forward in Patients With Influenza-Associated ARDS?
经验性抗真菌治疗是否是流感相关急性呼吸窘迫综合征患者的下一步治疗方向？
Florian Reizine and Jean-Pierre Gangneux
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e494–e496, https://doi.org/10.1093/cid/ciaf508
39
Valley Fever in Central California: Diagnosis is Not the Finish Line, the Real Gap is Longitudinal Care
加利福尼亚州中部山谷热：诊断并非终点，真正的差距在于纵向护理
Geetha Sivasubramanian
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e497–e502, https://doi.org/10.1093/cid/ciaf728
Hepatitis（肝炎）
40
The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia
澳大利亚接受阿片类激动剂治疗者的丙型肝炎治疗流程
Samara Griffin and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e503–e510, https://doi.org/10.1093/cid/ciaf352
41
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)
西班牙20多年来（2002-2023年）HIV感染者中丙型肝炎病毒感染流行率的趋势
Juan Berenguer and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e511–e520, https://doi.org/10.1093/cid/ciaf407
42
Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy
丙型肝炎围产期和产后治疗流程中的差距：孕期治疗的理由
Andrew B Mendlowitz and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e521–e533, https://doi.org/10.1093/cid/ciaf578
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
43
Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
艾巴利珠单抗和来那卡帕韦联合治疗多重耐药HIV-1：病例系列研究
Charlotte Rolle and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e534–e540, https://doi.org/10.1093/cid/ciaf597
44
New Strategies for a Vexing Problem: Injectables to the Rescue for People With Multidrug-Resistant HIV
棘手问题的新策略：注射剂助力多重耐药HIV感染者
William R Short and Onyema E Ogbuagu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e541–e543, https://doi.org/10.1093/cid/ciaf600
45
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
反弹效应：HIV感染者停用低剂量司美格鲁肽后会发生什么
Kristine M Erlandson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e544–e548, https://doi.org/10.1093/cid/ciaf652
46
Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况
Elizabeth C Arant and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e549–e557, https://doi.org/10.1093/cid/ciaf656
47
Infections After Kidney Transplantation from Donors with HIV to Recipients with HIV: Insights, Prevention, and the Path Forward
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况：见解、预防和未来方向
Abhay Dhand and Stephanie M Pouch
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e558–e560, https://doi.org/10.1093/cid/ciaf657
Respiratory Infections（呼吸道传染病）
48
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus
成人呼吸道合胞病毒感染的多病共存情况及严重院内结局
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e561–e570, https://doi.org/10.1093/cid/ciaf405
49
Characterizing Treatment Adherence Trajectories in the endTB Multisite Cohort of Drug-Resistant Tuberculosis Patients: An Application of Group-Based Trajectory Modeling
在endTB多站点耐药结核病患者队列中描述治疗依从性轨迹：基于组别的轨迹建模应用
Stephanie Law and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e571–e579, https://doi.org/10.1093/cid/ciaf467
50
Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States—2017–2020
2017 - 2020年美国按流感类型和亚型划分的住院成人流感患者临床表现严重程度及预后
Seana Cleary and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e580–e588, https://doi.org/10.1093/cid/ciaf545
51
Reported Tuberculosis Symptoms: An Inadequate Classifier of Disease State
报告的结核病症状：疾病状态分类的不足指标
Nicky McCreesh and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e589–e594, https://doi.org/10.1093/cid/ciaf611
Sexually Transmitted Infections（性传播感染）
52
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
2023 - 2024年更新版（单价XBB.1.5）新冠疫苗对SARS-CoV-2奥密克戎XBB和BA.2.86/JN.1谱系住院的有效性及临床严重程度比较——IVY网络，26家医院，2023年10月18日 - 2024年3月9日
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e595–e603, https://doi.org/10.1093/cid/ciae405
53
High Prevalence of Haemophilus ducreyi Among Patients With Suspected Primary syphilis in Malawi, 2019–2022
2019 - 2022年马拉维疑似原发性梅毒患者中杜克雷嗜血杆菌的高流行率
Mitch M Matoga and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e604–e611, https://doi.org/10.1093/cid/ciaf114
54
Characteristics Associated With Disseminated Gonococcal Infections vs Uncomplicated Gonorrhea: A California Case-control Study, 2021–2022
与播散性淋球菌感染（而非单纯性淋病）相关的特征：2021 - 2022年加利福尼亚病例对照研究
Kelly A Johnson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e612–e615, https://doi.org/10.1093/cid/ciaf311
Viral Infections（病毒性感染）
55
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men
男男性行为者肛门人乳头瘤病毒感染进展为疾病的情况
Joel M Palefsky and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e616–e625, https://doi.org/10.1093/cid/ciaf584
Correspondence（读者来信）
56
Cardiac Complications of Mycoplasma pneumoniae: Overlooked Confounders, Biomarkers, and Host-Driven Shifts
肺炎支原体感染的心脏并发症：被忽视的混杂因素、生物标志物及宿主驱动的变化
Shiuan-Chih Chen and Ming-Cheng Lin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e626–e627, https://doi.org/10.1093/cid/ciaf609
57
Mycoplasma pneumoniae–Associated Cardiac Complications Revisited
重新审视肺炎支原体相关心脏并发症
Daniel Grupel and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e627–e628, https://doi.org/10.1093/cid/ciaf610
58
Screening for Anal Cancer Is Associated With Real Harms and Questionable Benefits
肛门癌筛查存在实际危害且益处存疑
Chris Kenyon
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e628, https://doi.org/10.1093/cid/ciaf613
59
Anal Cancer Screening: A Balanced Approach is Necessary
肛门癌筛查：需采取平衡的方法
Hayden S Andrews and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e628–e629, https://doi.org/10.1093/cid/ciaf614
60
Collateral Benefits and Methodological Limits of Respiratory Syncytial Virus Immunization for Infant Otitis Media and Antibiotic Use
呼吸道合胞病毒免疫接种对婴儿中耳炎和抗生素使用的附带益处及方法学局限
Tsai Ling Ting and Kai-Lun Sheu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e629–e630, https://doi.org/10.1093/cid/ciaf640
61
Interpretation of Respiratory Syncytial Virus Immunization Impact on Pediatric Acute Otitis Media: Key Considerations
解读呼吸道合胞病毒免疫接种对儿童急性中耳炎的影响：关键考量因素
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e630–e631, https://doi.org/10.1093/cid/ciaf641
62
A Possible Increase in Penicillin-Resistant Strains of Treponema pallidum
梅毒螺旋体青霉素耐药菌株可能增加
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e631–e632, https://doi.org/10.1093/cid/ciaf643
63
Surveillance of Resistance-Associated Mutations in Treponema pallidum
梅毒螺旋体耐药相关突变的监测
Kai-Hsiang Chen and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e632–e633, https://doi.org/10.1093/cid/ciaf645
64
Does Empirical Antifungal Therapy Reduce IAPA in Influenza-Associated ARDS? Methodological Concerns on Diagnosis, Surveillance, and Clinical Heterogeneity
经验性抗真菌治疗能否减少流感相关急性呼吸窘迫综合征（IAPA）的发生？诊断、监测和临床异质性方面的方法学问题
Ming Xue and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e633–e634, https://doi.org/10.1093/cid/ciaf661
65
Empirical Antifungal Therapy and IAPA in Influenza-Associated ARDS: Insights from Real-World Data
流感相关急性呼吸窘迫综合征中的经验性抗真菌治疗和IAPA：来自现实数据的见解
Stefan Hatzl and Robert Krause
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e634, https://doi.org/10.1093/cid/ciaf664
Clinical Infectious Diseases Volume 82 Issue Supplement_2
临床传染病学 82卷 增刊2期
https://academic.oup.com/cid/issue/82/Supplement_2
SUPPLEMENT（增刊）
Advancing Tuberculosis Research Through RePORT International: Enhancing Treatment Outcomes, Predicting Disease Progression, and Improving Diagnosis
通过结核病区域性前瞻性观察研究国际联盟（RePORT International）推动结核病研究：提高治疗效果、预测疾病进展及改善诊断
SUPPLEMENT ARTICLES（增补论著）
1
A Narrative Review of the Regional Prospective Observational Research in Tuberculosis International Consortium: Sharing Diverse Data and Specimens in the Fight Against Tuberculosis
结核病区域性前瞻性观察研究国际联盟的叙述性综述：在抗击结核病中共享多样数据和样本
Rajita Bhavaraju and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S53–S59, https://doi.org/10.1093/cid/ciag151
2
Long-term Sequelae of Pulmonary Tuberculosis: A Narrative Review
长期肺部结核后遗症：一项叙述性综述
Akshay N Gupte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S60–S67, https://doi.org/10.1093/cid/ciag123
3
From Exposure to Disease: Predicting Tuberculosis Progression
从接触感染到发病：预测结核病进展
Mariana Araújo-Pereira and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S68–S74, https://doi.org/10.1093/cid/ciag125
4
Asymptomatic Tuberculosis Across the Disease Spectrum: A Scoping Review of Epidemiology, Diagnosis, and Public Health Implications
疾病谱中的无症状结核：一项关于流行病学、诊断和公共卫生影响的范围综述
Beatriz Barreto Duarte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S75–S84, https://doi.org/10.1093/cid/ciag150
Clinical Infectious Diseases Volume 82 Issue 4
临床传染病学 82卷 4期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时光的传染病学技艺）
1
La Petite Vérole
天花
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page i, https://doi.org/10.1093/cid/ciag118
In the Literature（文献精选）
2
In the Literature
文献精选
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag013
Joint Editorial（联合社论）
3
Protocols for Randomized Controlled Trials: Advancing Transparency in Infectious Diseases
随机对照试验方案：推动传染病领域透明度提升
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page 557, https://doi.org/10.1093/cid/ciag198
Clinical Dilemmas in Infectious Diseases（临床传染病疑难杂症）
4
Uncertain Terrain
不确定的领域
Kap Sum Foong and Sara W Dong
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 558–561, https://doi.org/10.1093/cid/ciaf283
Voices of ID（传染病之声）
5
Lessons I Learned from Our Soldier
我从我们的士兵身上学到的经验
Mitchell J Schwaber
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 562–563, https://doi.org/10.1093/cid/ciaf433
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
6
Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South
美国南部城市由瑞安·怀特资助的诊所中，HIV-1病毒血症患者使用长效卡博特韦/利匹韦林、来那卡帕韦和艾巴利珠单抗的情况
Jonathan A Colasanti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 564–574, https://doi.org/10.1093/cid/ciaf425
7
In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort
矛盾现象：在多中心艾滋病队列研究/妇女跨机构HIV研究联合队列中，尽管干燥血斑中磷酸替诺福韦水平低，但仍能实现病毒抑制
Sarah C Mann and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 575–582, https://doi.org/10.1093/cid/ciaf509
8
Prognostic Value of Blood Epigenetic Biomarkers of Aging in Persons With Well-Controlled HIV-1 Infection
血液衰老表观遗传生物标志物在HIV-1感染控制良好人群中的预后价值
Patricia Martínez-Martín and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 583–591, https://doi.org/10.1093/cid/ciaf537
9
HIV Resistance to Dolutegravir Varies With Coadministered Agents
HIV对多替拉韦的耐药性随联合用药的不同而有所差异
Ingrid A Beck and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 592–596, https://doi.org/10.1093/cid/ciaf481
Immunocompromised Hosts（免疫功能低下宿主）
10
Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients
基于巨细胞病毒细胞介导免疫的莱特莫韦预防可改善异体基因造血干细胞移植受者的预后
Luxiang Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 597–606, https://doi.org/10.1093/cid/ciaf410
11
Changing Clinical and Laboratory Characteristics of Progressive Multifocal Leukoencephalopathy: A Retrospective National Cohort Study
进行性多灶性白质脑病临床和实验室特征的变化：一项回顾性全国队列研究
Ilaria Mainardi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 607–617, https://doi.org/10.1093/cid/ciaf501
12
Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort
嵌合抗原受体T细胞疗法后呼吸道合胞病毒感染：一项多中心回顾性队列研究中的风险因素和预后
Maria Isabel Sotelo-Alva and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 618–621, https://doi.org/10.1093/cid/ciag052
Respiratory Infections（呼吸道感染）
13
Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update
美国传染病学会（IDSA）立场声明：为何IDSA未认可《2025年社区获得性肺炎指南》更新版
Michael Klompas and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 622–624, https://doi.org/10.1093/cid/ciaf625
14
We Dissent: Lessons From the 2025 Community-Acquired Pneumonia Guidelines
我们持不同意见：从《2025年社区获得性肺炎指南》中汲取的教训
Leila S Hojat and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 625–629, https://doi.org/10.1093/cid/ciaf626
15
Associations Between Antibiotic Use and Outcomes in Patients Hospitalized With Community-Acquired Pneumonia and Positive Respiratory Viral Assays
社区获得性肺炎且呼吸道病毒检测呈阳性住院患者抗生素使用与预后的关联
Brett Biebelberg and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 630–638, https://doi.org/10.1093/cid/ciaf687
16
Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study
联合β-内酰胺类药物治疗社区获得性肺炎的住院患者中，阿奇霉素与多西环素疗效的比较：一项多中心匹配队列研究
Yewande E Odeyemi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 639–647, https://doi.org/10.1093/cid/ciaf252
17
Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia
针对中度免疫功能低下肺炎住院患者，经验性抗生素对临床预后的目标试验模拟研究
Louis Saravolatz and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 648–657, https://doi.org/10.1093/cid/ciaf344
18
Impact of Respiratory Syncytial Virus Immunization on the Rate of Pediatric Acute Otitis Media: A Time-series Analysis
呼吸道合胞病毒免疫接种对儿童急性中耳炎发生率的影响：一项时间序列分析
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 658–664, https://doi.org/10.1093/cid/ciaf564
Vaccines（疫苗）
19
LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial
使用LC16m8针对高危人群进行猴痘暴露前预防：一项开放标签随机试验
Nobumasa Okumura and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 665–672, https://doi.org/10.1093/cid/ciaf074
20
Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial
在感染人类免疫缺陷病毒的女性中，接种2剂与3剂九价人乳头瘤病毒疫苗的免疫原性和安全性：Papillon随机试验
Deborah Konopnicki and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 673–681, https://doi.org/10.1093/cid/ciaf241
21
Screening and Vaccination Rates for Tetanus, Hepatitis A, and Hepatitis B Among Individuals With Substance Use Disorders Hospitalized in an Integrated US Health System
在美国综合医疗机构中住院的成瘾性患者的破伤风、甲型肝炎和乙型肝炎筛查及接种率
Jennifer H Ku and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 682–688, https://doi.org/10.1093/cid/ciaf251
22
Atrial Fibrillation After Respiratory Syncytial Virus Vaccination Among Older Adults
老年人接种呼吸道合胞病毒疫苗后发生心房颤动的情况
Morgan Birabaharan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 689–691, https://doi.org/10.1093/cid/ciae649
23
Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations
比较流感疫苗有效性的方法，以指导可能的优先产品推荐
Edward A Belongia and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 692–697, https://doi.org/10.1093/cid/ciaf563
Viral Infections（病毒性感染）
24
Clinical Features and Outcomes of Human Herpesvirus-6 DNAemia in Critically Ill Patients: A Retrospective Multicenter Analysis
危重患者人类疱疹病毒6型DNA血症的临床特征和预后：一项回顾性多中心分析
Margot Combet and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 698–708, https://doi.org/10.1093/cid/ciaf199
25
Kaposi Sarcoma–Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States
美国HIV感染肾捐赠者和移植受者中卡波西肉瘤相关疱疹病毒的风险和疾病
Puja H Nambiar and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 709–719, https://doi.org/10.1093/cid/ciaf229
26
Clinical Outcomes of Mpox Disease in Patients Treated With Tecovirimat
接受特考韦瑞治疗的猴痘病患者的临床预后
Ciarra Leocadio and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 720–726, https://doi.org/10.1093/cid/ciaf520
27
Effective Antivirals in Pandemic Preparedness: Past Mistakes, Future Needs
大流行防范中的有效抗病毒药物：过去的错误，未来的需求
Antonios-Periklis Panagiotopoulos and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 727–733, https://doi.org/10.1093/cid/ciaf648
Photo Quizzes（影像问答）
28
From Soil to Skin: An Unexpected Cause of Necrotizing Cellulitis
从土壤到皮肤：坏死性蜂窝织炎的意外病因
Erica Peak and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 734–737, https://doi.org/10.1093/cid/ciaf555
29
A 67-year-Old Immunocompromised Male Presenting With Right Upper-Quadrant Abdominal Pain and Hepatic Lesions
一例67岁免疫功能低下男性，出现右上腹疼痛和肝脏病变
Sara Yousef Zadeh Shoushtari and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 738–741, https://doi.org/10.1093/cid/ciaf729
Bacterial Infections（细菌性感染）
30
Patient-reported Perceptions, Experiences, and Preferences Around Intravenous and Oral Antibiotics for the Treatment of Staphylococcus aureus Bacteremia: A Descriptive Qualitative Study
金黄色葡萄球菌菌血症患者对静脉和口服抗生素治疗的自我报告认知、体验和偏好：一项描述性质性研究
Genevieve Walls and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e635–e642, https://doi.org/10.1093/cid/ciaf522
31
Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes
金黄色葡萄球菌菌血症临床亚型的可重复性识别
Maaike C Swets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e643–e651, https://doi.org/10.1093/cid/ciaf655
32
Disease Trends and Mortality From Invasive Pneumococcal Disease: A Long-Term Population-Based Study
侵袭性肺炎球菌病的疾病趋势和死亡率：一项长期人群基础研究
Hörður Tryggvi Bragason and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e652–e661, https://doi.org/10.1093/cid/ciaf670
33
When and How to Use Subcutaneous Antibiotics
皮下注射抗生素的使用时机和方法
Stefano Di Bella and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e662–e673, https://doi.org/10.1093/cid/ciaf691
Clinical Trials（临床实验）
34
Using the Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) Clinical Trial to Influence Institutional Practice Transformation Towards Earlier Transition to Oral Antibiotics
利用口服与肠外抗菌治疗比较（COPAT）临床实验推动机构实践转型，以更早地过渡到口服抗生素治疗
Joy J Juskowich and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e674–e681, https://doi.org/10.1093/cid/ciaf707
35
The Fate of Oral Meds
口服药物的命运
Monica V Mahoney
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e682–e683, https://doi.org/10.1093/cid/ciaf708
36
Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies
接受吉泊西汀或呋喃妥因治疗的无并发症尿路感染患者的早期症状反应：两项关键性3期研究的汇总分析
Amanda J Sheets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e684–e692, https://doi.org/10.1093/cid/ciaf722
37
Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial
HIV-1一线治疗失败人群中耐药突变发生率和决定因素的区域差异：D2EFT 3b/4期临床试验的子研究
Billal Musah Obeng and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e693–e704, https://doi.org/10.1093/cid/ciaf739
38
What's Hot This Year in ID Clinical Science 2025
2025年传染病临床学科领域的年度热点
Jeffrey A Freiberg and Patty W Wright
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e705–e709, https://doi.org/10.1093/cid/ciaf740
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
39
Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women With HIV
阴道雌二醇对HIV感染女性绝经生殖泌尿综合征、阴道微生物群和黏膜免疫介质的影响
Kerry Murphy and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e710–e719, https://doi.org/10.1093/cid/ciaf669
40
Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin
在接受比克替拉韦/恩曲他滨/丙酚替诺福韦和利福平治疗的HIV相关结核病成人患者中，每日两次丙酚替诺福韦的药代动力学
Emmanuella Chinonso Osuala and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e720–e727, https://doi.org/10.1093/cid/ciaf732
41
Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care
整合HIV和兴奋剂使用障碍治疗：在HIV护理中开展应急管理试点实施效果试验
Ayesha Appa and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e728–e734, https://doi.org/10.1093/cid/ciag006
42
Hepatitis B Reactivation in a US Cohort of People With HIV and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity
美国HIV和乙型肝炎核心抗体阳性人群在转换为无抗乙肝病毒活性的抗逆转录病毒治疗后乙型肝炎复发的队列研究
Rachel V Denyer and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e735–e742, https://doi.org/10.1093/cid/ciag001
43
Hepatitis B Virus Reactivation in People With HIV After Treatment With Non-hepatitis B Virus-Active Antiretroviral Therapy
接受无抗乙肝病毒活性的抗逆转录病毒治疗的HIV感染者乙型肝炎病毒复发情况
Amir M Mohareb and Anders Boyd
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e743–e745, https://doi.org/10.1093/cid/ciag002
44
The Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States
终止美国疾病控制与预防中心对HIV检测资助的潜在影响：对18个州的建模研究
Ruchita Balasubramanian and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e746–e754, https://doi.org/10.1093/cid/ciag038
45
Cutting Federal Funds for HIV Testing Means Not Ending the HIV Epidemic
削减HIV检测的联邦资金意味着无法终结HIV流行
Sarah E Scott and Joshua A Barocas
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e755–e756, https://doi.org/10.1093/cid/ciag039
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
46
Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital
西拉查医院普通内科病房强化碳青霉烯类耐药肠杆菌科细菌预防计划的整群随机对照试验
Apiradee Taweesuk and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e757–e764, https://doi.org/10.1093/cid/ciaf523
47
Risk Factors Associated With Progression to Clinical Candida auris Infection Among Adults With Previous Colonization—Florida, 2019–2023
2019-2023年佛罗里达州既往定植的成人进展为临床耳念珠菌感染的相关风险因素
Katharine E Saunders and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e765–e772, https://doi.org/10.1093/cid/ciaf551
48
Using Generative Artificial Intelligence to Identify Central Line–associated Bloodstream Infections
利用生成式人工智能识别中心静脉导管相关血流感染
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e773–e780, https://doi.org/10.1093/cid/ciaf636
49
Infection Control in Carceral Facilities
监狱设施中的感染控制
Amadin A Olotu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e781–e790, https://doi.org/10.1093/cid/ciaf479
50
Infection Prevention and Control in Carceral Settings
监狱环境中的感染预防与控制
April N McDougal and Lara B Strick
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e791–e793, https://doi.org/10.1093/cid/ciaf480
51
Impact of Discontinuation of Contact Precautions on Healthcare-associated Extended Spectrum β-Lactamase-Producing Escherichia coli in a Large Tertiary Care Hospital: An Interrupted Time-series Analysis
一家大型三级医院停止接触预防措施对医院获得性产超广谱β-内酰胺酶大肠埃希菌的影响：一项中断时间序列分析
Stefano Musumeci and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e794–e798, https://doi.org/10.1093/cid/ciaf594
Respiratory Infections（呼吸道感染）
52
Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis
美国医疗保险参保老年人因需就医的呼吸道合胞病毒疾病后患吉兰-巴雷综合征的风险评估：一项自我对照病例系列分析
Caihua Liang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e799–e806, https://doi.org/10.1093/cid/ciaf621
53
Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2
独立检测以加速甲型流感、乙型流感和严重急性呼吸系统综合征冠状病毒2型侧流层析检测法的开发
Anuradha Rao and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e807–e815, https://doi.org/10.1093/cid/ciaf660
54
Diagnostic Yield of Tongue Swab- Compared to Sputum-Based Molecular Testing for Tuberculosis in Four High-Burden Countries
在四个高负担国家，与痰液分子检测相比，舌拭子检测对结核病的诊断效果
Caitlin A Moe and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e816–e823, https://doi.org/10.1093/cid/ciag077
55
Are We Ready for the Gift Tongues Can Give to Tuberculosis?
我们准备好接受舌头为结核病诊断带来的“馈赠”了吗？
Michael R Barer
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e824–e825, https://doi.org/10.1093/cid/ciag078
Sexually Transmitted Infections（性传播感染）
56
Evaluating the Impact of Implementing and Scaling-Up the Use of Syphilis Rapid/Point-of-Care Tests: An Interrupted Time Series Analysis of New Syphilis Positivity Rates in Alberta, Canada
评估实施和扩大梅毒快速/即时检测使用的影响：加拿大阿尔伯塔省新发梅毒阳性率的中断时间序列分析
L Alexa Thompson and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e826–e835, https://doi.org/10.1093/cid/ciaf651
57
Human Papillomavirus-Related Anal Precancerous Lesions in Men Who Have Sex With Men: A Comparative Study of Pre-exposure Prophylaxis Users and HIV-Positive Individuals
男男性行为者中与人乳头瘤病毒相关的肛门癌前病变：暴露前预防用药者与HIV阳性者的对比研究
Magali Surmont and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e836–e842, https://doi.org/10.1093/cid/ciaf724
58
Is 3 Really What We Need? Relative Effectiveness of Benzathine Penicillin G and Doxycycline Treatment Regimens for Late or Unknown Duration Syphilis in 6 US Jurisdictions, 2016–2021
我们需要“3”吗？2016-2021年美国6个司法管辖区晚期或病程不明梅毒患者使用苄星青霉素G和多西环素治疗方案的相对疗效
River A Pugsley and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e843–e851, https://doi.org/10.1093/cid/ciag099
59
Strong Real-World Evidence That a Single Dose of Benzathine Penicillin G or a 28-Day Course of Oral Doxycycline Is Not Inferior to 3 Doses of Benzathine Penicillin G for the Treatment of Late Latent or Unknown Duration Syphilis
强力现实证据表明，单剂苄星青霉素G或28天口服多西环素治疗晚期潜伏梅毒或病程不明梅毒的疗效并不逊于3剂苄星青霉素G
Noah Kojima and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e852–e854, https://doi.org/10.1093/cid/ciag101
Vaccines（疫苗）
60
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
对≥50岁成年人，在初次接种12个月后再次接种针对呼吸道合胞病毒的mRNA疫苗mRNA-1345的安全性、耐受性和免疫原性
Jaya Goswami and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e855–e862, https://doi.org/10.1093/cid/ciaf515
61
Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine
在NVX-CoV2373重组蛋白疫苗PREVENT-19有效性试验中，抗体标志物作为严重新型冠状病毒肺炎风险免疫相关因素的分析
Youyi Fong and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e863–e874, https://doi.org/10.1093/cid/ciaf558
62
Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?
现在是时候重新评估全球人乳头瘤病毒疫苗接种的目标年龄了吗？
Edie Brassington and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e875–e883, https://doi.org/10.1093/cid/ciaf679
63
Preschool or Infant Human Papillomavirus Immunization?
学龄前还是婴儿期接种人乳头瘤病毒疫苗？
Mark A Kane and Eduardo L Franco
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e884–e886, https://doi.org/10.1093/cid/ciaf678
Correspondence（读者来信）
64
Caution in Interpreting Equivalence From Nonsignificant Findings in Antiretroviral Switch Studies
谨慎解读抗逆转录病毒药物转换研究中非显著性结果得出的等效性结论
Esteban Martinez
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e887–e888, https://doi.org/10.1093/cid/ciaf675
65
Clarifying INSTINCT: Switching From Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Shows Comparable Inflammatory and Weight Outcomes
阐明INSTINCT研究：从多替拉韦/拉米夫定转换为比克替拉韦/恩曲他滨/丙酚替诺福韦显示出相似的炎症和体重结果
Sergio Serrano-Villar and Santiago Moreno
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e888–e889, https://doi.org/10.1093/cid/ciaf676
66
Can Doxycycline Prophylaxis Indirectly Reduce Congenital Syphilis?
多西环素预防能否间接降低先天性梅毒的发生率？
Kalpana Gopalkrishnan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e889–e891, https://doi.org/10.1093/cid/ciaf694
67
The Urgency of Now: Congenital Syphilis in the Doxycycline Post-exposure Prophylaxis Era
迫在眉睫：多西环素暴露后预防时代的先天性梅毒问题
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page e891, https://doi.org/10.1093/cid/ciaf695
68
Routine HIV RNA Testing During Injectable Cabotegravir and Oral Preexposure Prophylaxis Use
注射用卡博特韦和口服暴露前预防用药期间进行常规HIV RNA检测
Angelo Roberto Raccagni and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e891–e892, https://doi.org/10.1093/cid/ciaf702
69
Simplifying Testing for Human Immunodeficiency Virus During Pre-exposure Prophylaxis Monitoring
简化暴露前预防监测期间的人类免疫缺陷病毒检测
Weiming Zhu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e892–e893, https://doi.org/10.1093/cid/ciaf703
70
Methodological Considerations in Evaluating Oral Antivirals for B-Cell-Depleted Patients
评估B细胞耗竭患者口服抗病毒药物的方法学考量
Wenjing Chen and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e893–e894, https://doi.org/10.1093/cid/ciaf717
71
Target Trial Emulation of Oral Antivirals for B-Cell-Depleted COVID-19 Patients—Reply to Chen et al
B细胞耗竭型新型冠状病毒肺炎患者口服抗病毒药物的靶试验模拟——回复Chen等人的评论
Xiaofeng F Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e894–e895, https://doi.org/10.1093/cid/ciaf718
72
Misleading Conclusion That Is Not in Accordance With the Results of the Reported Randomized, Controlled Trial
与所报告的随机对照试验结果不符的误导性结论
Charlotte Strøm
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e895–e896, https://doi.org/10.1093/cid/ciaf659
73
Vaccine Policy Pendulum: A Lesson From Japan
疫苗政策摇摆不定：日本的教训
Masaki Machida and Wakaba Fukushima
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e896–e897, https://doi.org/10.1093/cid/ciaf689
74
Herpes Zoster, Vaccine, and Stroke Risk
带状疱疹、疫苗与中风风险
Shih-Wei Lai and Sheng-Chun Chiu
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e897–e898, https://doi.org/10.1093/cid/ciaf725
Clinical Infectious Diseases Volume 82 Issue Supplement_4
临床传染病学 82卷 增刊4期
https://academic.oup.com/cid/issue/82/Supplement_4
SUPPLEMENT（增刊）
IDWeek Industry Highlights 2025
传染病之周2025 行业亮点
SUPPLEMENT ARTICLES（增补论著）
1
Selected Industry Highlights From IDWeek 2025
传染病之周2025 精选行业亮点
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S85–S86, https://doi.org/10.1093/cid/ciag206
2
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
HIV感染者内脏腹部脂肪过多的不同表现：两例临床病例展示特沙莫瑞林与胰高血糖素样肽-1受体激动剂的不同治疗路径
Robin Beach and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S87–S91, https://doi.org/10.1093/cid/ciag121
3
Metagenomic Next-generation Sequencing in Central Nervous System Infections: Clinical Strategies, Evidence, and Best Practices
宏基因组二代测序在中枢神经系统感染中的应用：临床策略、证据与最佳实践
Greer Waldrop and Sumanth P Reddy
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S92–S99, https://doi.org/10.1093/cid/ciag120
Clinical Infectious Diseases Volume 82 Issue 5
临床传染病学 82卷 5期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Vaccination Detail, Detroit Industry
疫苗接种细节，底特律工业
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page i, https://doi.org/10.1093/cid/ciag119
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag180
Voices of ID（传染病之声）
3
Infected With the Academic Bug
染上学术热
Sigrun Einarsdottir
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 743–744, https://doi.org/10.1093/cid/ciaf546
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
4
Predictive Value of C-reactive Protein for Hospitalization and Mortality Among People With Advanced HIV Disease in Uganda Receiving the World Health Organization-recommended Package of Care
C反应蛋白对乌干达接受世界卫生组织推荐治疗方案的晚期HIV疾病患者住院和死亡的预测价值
Elizabeth L Schwartz and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 745–752, https://doi.org/10.1093/cid/ciaf560
5
Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial
塞马谷肽对HIV感染者认知功能的影响：一项随机对照试验
Ornina Atieh and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 753–761, https://doi.org/10.1093/cid/ciaf577
6
Earlier Initiation of Treatment Following HIV Acquisition Reduces Non-AIDS-defining Malignancy Risk
HIV感染后尽早启动治疗可降低非艾滋病相关性恶性肿瘤风险
Iris A J van der Wulp and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 762–772, https://doi.org/10.1093/cid/ciaf595
7
Let's Get It Started: Early Antiretroviral Treatment After HIV Acquisition Reduces Non–AIDS-Defining Malignancies
让我们开始吧：HIV感染后尽早启动抗逆转录病毒治疗可减少非艾滋病相关性恶性肿瘤
Nancy Crum
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 773–775, https://doi.org/10.1093/cid/ciaf596
8
Trends in Age-Related Health Outcomes in People with HIV in Spain, 2006–2023
2006–2023年西班牙HIV感染者年龄相关健康结局的趋势
Javier Martínez-Sanz and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 776–784, https://doi.org/10.1093/cid/ciaf622
9
Emergent HIV-1 Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens
当代抗逆转录病毒方案随机试验中新发HIV-1耐药性
Josep M Llibre and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 785–798, https://doi.org/10.1093/cid/ciaf471
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
10
Mycobacterium tuberculosis Transmission in Healthcare Settings: A Systematic Review of Frequency, Risk Factors, and Exposure Conditions
医疗机构中结核分枝杆菌传播：频率、危险因素及暴露条件的系统综述
Fizza Manzoor and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 799–807, https://doi.org/10.1093/cid/ciag053
Medical Microbiology（医学微生物学）
11
Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital
脑脊液宏基因组二代测序：一家三级转诊医院首年经验
Sergio Alvarez Mulett and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 808–814, https://doi.org/10.1093/cid/ciaf390
12
Navigating Nomenclature in Patient Care: Taxonomy Considerations From the College of American Pathologists’Microbiology Committee
患者诊疗中的命名导航：美国病理学家学会微生物学委员会的分类学考量
Jennifer Dien Bard and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 815–821, https://doi.org/10.1093/cid/ciaf474
13
Implementing Point-of-Care Testing in Infectious Diseases
在感染性疾病中实施床旁检测
Jean-Claude Nguyen Van and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 822–828, https://doi.org/10.1093/cid/ciaf650
Mycobacterial Infections（分枝杆菌感染）
14
Impact of Diabetes Mellitus in Tuberculosis (TB) Patients on TB Transmission
糖尿病对结核病（TB）患者TB传播的影响
Chuan-Chin Huang and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 829–840, https://doi.org/10.1093/cid/ciaf647
15
Association of Mycobacterium avium paratuberculosis With Crohn's Disease: A Large Multicenter Study From a Tuberculosis-Endemic Region
副结核分枝杆菌与克罗恩病的关联：来自结核病流行地区的一项大型多中心研究
Sudheer Kumar Vuyyuru and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 841–847, https://doi.org/10.1093/cid/ciaf738
16
Short-Course Tuberculosis Preventive Therapy in a High Migration Setting: Early Experience With 1HP in Cook County, Illinois
高移民背景下的短程结核病预防性治疗：库克县（伊利诺伊州）1HP方案的早期经验
Samuel Starke and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 848–851, https://doi.org/10.1093/cid/ciaf723
17
Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort Study
低剂量英夫利昔单抗在中枢神经系统结核炎性并发症中的作用：一项回顾性队列研究
Selwyn Selva Kumar D and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 852–856, https://doi.org/10.1093/cid/ciaf573
18
Targeting Inflammation in Tuberculous Meningitis Treatment
靶向结核性脑膜炎治疗中的炎症
Guy E Thwaites
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 857–859, https://doi.org/10.1093/cid/ciaf574
Pediatric and Maternal Infectious（儿科与孕产妇感染）
19
A 15-year Single-center Analysis of Late-onset Group B Streptococcus Infection Correlating Clinical Severity With Pathogen Virulence Determinants
晚发型B族链球菌感染的15年单中心分析：临床严重程度与病原体毒力因子的相关性
Carl Britto and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 860–867, https://doi.org/10.1093/cid/ciaf603
20
Evaluating Personal and Environmental Decolonization Strategies for Children With Skin and Soft Tissue Infection and Their Households — A Randomized Clinical Trial
评估皮肤和软组织感染儿童及其家庭的个人与环境去定植策略——一项随机临床试验
Alaina L Robinson and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 868–877, https://doi.org/10.1093/cid/ciaf627
Surgical Infectious Diseases（外科感染）
21
Impact of Vancomycin-Resistant Enterococci (VRE)–Active Perioperative Prophylaxis in Liver Transplant Patients Colonized by VRE
万古霉素耐药肠球菌（VRE）主动围手术期预防对VRE定植肝移植受者的影响
Giulia Jole Burastero and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 878–887, https://doi.org/10.1093/cid/ciaf121
22
Cephalosporins Versus Non-cephalosporin Antibiotics for Perioperative Prophylaxis in Primary Arthroplasty: A Systematic Review and Meta-Analysis
头孢菌素与非头孢菌素类抗生素在初次关节置换术围手术期预防中的比较：系统综述与荟萃分析
Rita Igwilo-Alaneme and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 888–900, https://doi.org/10.1093/cid/ciag172
Photo Quizzes（影像问答）
23
Safari Souvenir: A Case of Fever in a Returning Traveler
safari纪念品：一例返程旅行者发热病例
Nicole L Kusnik and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 901–903, https://doi.org/10.1093/cid/ciag129
24
Diagnostic Pitfalls—When First Appearances Can Deceive
诊断陷阱——当表象具有欺骗性
Annie Caldwell and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 904–907, https://doi.org/10.1093/cid/ciag044
Clinical Trials（临床试验）
25
Evaluation of a Remote Therapeutic Monitoring Device and Integrated Care Platform in Outpatient Parenteral Antimicrobial Therapy
远程治疗监测设备与综合护理平台在门诊肠外抗微生物治疗中的评估
Emily A Siegrist and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e899–e909, https://doi.org/10.1093/cid/ciag009
26
Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial
多替拉韦降低人T淋巴细胞病毒1型前病毒载量并改善神经系统预后：一项2期对照试验
Carlos Brites and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e910–e920, https://doi.org/10.1093/cid/ciag163
27
Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy
多替拉韦似乎可降低人T淋巴细胞病毒1型（HTLV-1）前病毒载量：HTLV-1相关脊髓病治疗的新兴理性方法
Eric A Meyerowitz
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e921–e922, https://doi.org/10.1093/cid/ciag164
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers
长效新冠与急性新冠疫苗接种后综合征的临床表现重叠：表型、严重程度及生物标志物
Lawrence Purpura and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e923–e931, https://doi.org/10.1093/cid/ciaf624
29
Integrating Genomic Data into Test-negative Designs for Estimating Lineage-specific COVID-19 Vaccine Effectiveness
将基因组数据整合入检测阴性设计以估计谱系特异性COVID-19疫苗有效性
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e932–e941, https://doi.org/10.1093/cid/ciag059
Hepatitis（肝炎）
30
Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With HIV
HIV感染者经直接抗病毒药物治疗丙型肝炎病毒后肝细胞癌的风险
Daniela K van Santen and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e942–e950, https://doi.org/10.1093/cid/ciaf635
31
Fatal Overdose, Acute Viral Hepatitis, and HIV Attributed to Injection Drug Use, Appalachian Region of the United States, 2000–2023
阿巴拉契亚地区2000–2023年注射吸毒导致的致命过量、急性病毒性肝炎及HIV
Danae Bixler and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e951–e959, https://doi.org/10.1093/cid/ciaf730
32
Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023–September 2024
利用大型商业实验室剩余血清估算丙型肝炎患病率及病毒清除率：2023年11月至2024年9月
Megan G Hofmeister and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e960–e966, https://doi.org/10.1093/cid/ciag007
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
33
State AIDS Drug Assistance Programs’Contribution to the US Viral Suppression, 2015–2022
美国各州艾滋病药物援助项目对全美病毒抑制的贡献，2015–2022年
Kathleen A McManus and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e967–e973, https://doi.org/10.1093/cid/ciag034
34
Centering AIDS Drug Assistance Programs in the US HIV Response
将艾滋病药物援助项目置于美国HIV应对的核心
Benjamin P Linas
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e974–e975, https://doi.org/10.1093/cid/ciag035
35
Association of Immunodeficiency and HIV Viremia With Cervical Precancer and Cancer Risk Among Women With HIV in South Africa
南非HIV感染女性中免疫缺陷和HIV病毒血症与宫颈癌前病变及癌症风险的关联
Yann Ruffieux and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e976–e983, https://doi.org/10.1093/cid/ciag093
36
Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies
MK-8527（一种口服核苷逆转录酶转位抑制剂）在既往未接受过抗逆转录病毒治疗的HIV-1感染成人中的抗逆转录病毒活性、药代动力学及安全性：来自两项开放标签1期研究的结果
Russ P Carstens and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e984–e991, https://doi.org/10.1093/cid/ciag135
37
Point-of-Care Urine Tenofovir Drug-Level Feedback Counseling Improves Long-Term Pre-exposure Prophylaxis Adherence for US Men Who Have Sex With Men in Pilot RCT
床旁尿液替诺福韦药物浓度反馈咨询改善美国男男性行为者长期暴露前预防用药依从性——一项先导随机对照试验
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e992–e995, https://doi.org/10.1093/cid/ciag080
Mycobacterial Infections（分枝杆菌感染）
38
Diagnostic Accuracy of the STANDARD F TB-Feron FIA Assay for Tuberculosis Infection in Vietnam: A Cross-Sectional Study
STANDARD F TB-Feron FIA检测在越南结核感染诊断中的准确性：一项横断面研究
Han Thi Nguyen and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e996–e1004, https://doi.org/10.1093/cid/ciaf561
39
Asymptomatic Tuberculosis in Children With Household Exposure to Mycobacterium tuberculosis
有结核分枝杆菌家庭接触史儿童中的无症状结核病
Humphrey Mulenga and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1005–e1013, https://doi.org/10.1093/cid/ciaf562
40
Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment
利福平暴露及临床基线协变量对肺结核治疗反应影响的深入认识
Marie Wijk and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1014–e1022, https://doi.org/10.1093/cid/ciaf586
41
Tuberculosis Infection Screening Recommendations for Targeted Immunotherapies: Comparison of US Prescribing Information, Clinical Resources, and Quality Measures
靶向免疫治疗的结核感染筛查建议：美国处方信息、临床资源与质量指标的比较
Matthew T Murrill and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1023–e1035, https://doi.org/10.1093/cid/ciaf628
42
Pharmacokinetics of Dexamethasone in Tuberculous Meningitis
地塞米松在结核性脑膜炎中的药代动力学
Jose M Calderin and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1036–e1042, https://doi.org/10.1093/cid/ciaf642
43
One Piece in the Puzzle of Tuberculous Meningitis: Dexamethasone Pharmacokinetics
结核性脑膜炎拼图中的一块：地塞米松药代动力学
Tjip S van der Werf and Marieke G G Sturkenboom
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1043–e1044, https://doi.org/10.1093/cid/ciaf644
44
Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine—An Approach for Clinical Management
临床表型用于结核精准医学的未来前景——一种临床管理方法
Katarina Niward and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1045–e1052, https://doi.org/10.1093/cid/ciaf663
Pediatric and Maternal Infectious Diseases（儿科与孕产妇感染）
45
Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa
南非夸祖鲁-纳塔尔省接受新型及重新利用药物治疗耐多药/利福平耐药结核病的女性的母婴预后
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1053–e1062, https://doi.org/10.1093/cid/ciaf593
46
Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa
南非耐多药/利福平耐药结核病孕妇与全口服6个月方案：一例系列患者的经验
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1063–e1071, https://doi.org/10.1093/cid/ciag032
47
Human Cytomegalovirus (HCMV) Shedding and T-cell Immune Responses in HCMV-seropositive Women During Pregnancy and Postpartum: Prevalence, Natural History, and Risk Factors
HCMV血清阳性女性孕期及产后人巨细胞病毒（HCMV）排毒和T细胞免疫应答：患病率、自然史及危险因素
Shari Sapuan and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1072–e1082, https://doi.org/10.1093/cid/ciag076
Vaccines（疫苗）
48
Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old
奥密克戎BA.1适配BNT162b2 COVID-19疫苗第四剂在18–55岁成人中的安全性和免疫原性
Patricia Winokur and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1083–e1092, https://doi.org/10.1093/cid/ciag026
49
Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years
AS01E佐剂呼吸道合胞病毒（RSV）预融合F蛋白疫苗在18–49岁RSV高风险成人中与≥60岁成人的免疫原性和安全性比较
Essack Mitha and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1093–e1103, https://doi.org/10.1093/cid/ciag058
50
Real-World Effectiveness of RSVpreF and RSVpreF3 Vaccines in Preventing Hospitalization and Emergency Department Visits Associated With Respiratory Syncytial Virus in Older Adults: A Meta-analysis
RSVpreF和RSVpreF3疫苗在预防老年人RSV相关住院和急诊就诊中的真实世界有效性：一项荟萃分析
Dewan Md Sumsuzzman and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1104–e1111, https://doi.org/10.1093/cid/ciag107
51
Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345
实体器官移植受者的呼吸道合胞病毒疫苗接种：mRNA-1345三期试验中期结果
Erick F Mayer and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1112–e1121, https://doi.org/10.1093/cid/ciag108
Photo Quiz（影像问答）
52
Crusted, Chronic, and Confusing
结痂、慢性化与困惑
Luisa Hurtado-Rossi and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1122–e1125, https://doi.org/10.1093/cid/ciaf583
Correspondence（读者来信）
53
Unmasking the Hidden Guests: Referral and Secondary Infection Biases in Cutibacterium Endocarditis
揭开隐藏的访客：Cutibacterium心内膜炎中的转诊偏倚和二次感染偏倚
Shuo Li and Lin Wang
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page e1126, https://doi.org/10.1093/cid/ciaf733
54
Reply to Willoughby on the Demise of the Milwaukee Protocol for Rabies
对Willoughby关于密尔沃基狂犬病方案终结的回复
Alan C Jackson and Thiravat Hemachudha
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1126–e1127, https://doi.org/10.1093/cid/ciaf734
55
Estimating Vaccine Effectiveness Against Symptomatic Infection From Its Effectiveness Against Asymptomatic Infection
从无症状感染的疫苗有效性估算有症状感染的疫苗有效性
Eyal Shahar
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1127–e1128, https://doi.org/10.1093/cid/ciaf735
56
Contextualizing On-Therapy Resistance Development With Novel Antibiotics: Interplay Between Timing of Therapy Initiation and Critical Illness–Linked Pharmacokinetic/Pharmacodynamic Unpredictability
新型抗生素治疗中耐药产生的情境化解读：治疗启动时机与危重疾病相关药代动力学/药效学不可预测性之间的相互作用
Dilip Dubey and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1128–e1129, https://doi.org/10.1093/cid/ciag010
57
The Clinical Thermometer as the First Home Test for Infectious Disease
临床体温计：感染性疾病的首个家用检测工具
Michele Augusto Riva
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1129–e1130, https://doi.org/10.1093/cid/ciag030
58
Methodology Misrepresented: Correcting the Record on the American Thoracic Society Community-acquired Pneumonia Guideline Process
方法论被歪曲：更正美国胸科学会社区获得性肺炎指南制定过程的记录
Kevin C Wilson and Eyal Oren
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1130–e1131, https://doi.org/10.1093/cid/ciag040
59
Misleading Comments About the Impact of Early Bacillus Calmette-Guerin Vaccination on Neonatal and Infant Mortality
关于早期卡介苗接种对新生儿和婴儿死亡率影响的误导性评论
Peter Aaby and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1131–e1132, https://doi.org/10.1093/cid/ciag065
60
Questioning Non-inferiority: Methodological Concerns in the Meta-analysis of Oral vs Intravenous Therapy for Staphylococcus aureus Bacteremia
质疑非劣效性：金黄色葡萄球菌菌血症口服与静脉治疗荟萃分析中的方法学问题
Dawd S Siraj and Fauzia Hollnagel
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1132–e1133, https://doi.org/10.1093/cid/ciag070
61
Problems With Electronic Health Record Penicillin Allergy Mislabeling and Recommendations for Their Correction
电子健康记录中青霉素过敏标注错误的问题及纠正建议
David J Witt and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page e1134, https://doi.org/10.1093/cid/ciag086
62
Complex Problem, Digital Cure? Rethinking Penicillin Allergy Relabeling Using Technology-Enabled Care
复杂问题，数字解药？利用技术赋能护理重新思考青霉素过敏重新标注
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1135–e1137, https://doi.org/10.1093/cid/ciag084
Clinical Infectious Diseases Volume 82 Issue Supplement_5
临床传染病学 82卷 增刊5期
https://academic.oup.com/cid/issue/
SUPPLEMENT（增刊）
ADVANCE-ID: Conducting Innovative Clinical Trials and Promoting Access for Antibiotics in Asia
ADVANCE-ID：在亚洲开展创新临床试验并推动抗生素可及性
SUPPLEMENT ARTICLES（增补论著）
1
Advancing Clinical Evidence in Infectious Diseases: An Infectious Diseases Clinical Trials Network for Asia, the “Antimicrobial Resistance Hot Zone”
推进感染病临床证据：面向亚洲——这一"耐药热点区域"——的感染性疾病临床试验网络
David L Paterson
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S101–S104, https://doi.org/10.1093/cid/ciag122
2
Global Survey on the Management of Multidrug-resistant Gram-negative Bacilli: Divergence of Practice Between High-Income Countries and the Rest of the World
多重耐药革兰阴性杆菌管理的全球调查：高收入国家与世界其他地区的实践差异
Abi Manesh and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S105–S115, https://doi.org/10.1093/cid/ciag025
3
Efficacy and Safety of Newer Antibiotics Versus Generic Antibiotics for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
新型抗生素与仿制抗生素治疗医院获得性及呼吸机相关性细菌性肺炎的疗效与安全性：随机对照试验的系统综述与荟萃分析
Anh T K Nguyen and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S116–S125, https://doi.org/10.1093/cid/ciag045
4
Antibiotic Clinical Trials: A Review of the Past, Present Challenges, and Potential Solutions
抗生素临床试验：回顾过去、当前挑战及潜在解决方案
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S126–S137, https://doi.org/10.1093/cid/ciag017
5
Considerations in Designing Clinical Trials of Novel Antibacterial Agents Using a Superiority Design
采用优效性设计开展新型抗菌药物临床试验的考量
David L Paterson and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S138–S146, https://doi.org/10.1093/cid/ciag207
6
Consent Modes and Consent Rates in Randomized Controlled Trials for Severe Infections: A Scoping Review
严重感染随机对照试验中的知情同意方式与同意率：范围性综述
Yiyun Shou and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S147–S153, https://doi.org/10.1093/cid/ciaf715
7
Challenges to Accessing Newer Antibiotics for Multidrug-resistant Bacterial Infections in Asia: A Literature Review of Multi-Stakeholder Perspectives
亚洲多重耐药细菌感染中获取新型抗生素的挑战：多利益相关方视角的文献综述
Alec F Aligui and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S154–S161, https://doi.org/10.1093/cid/ciag024
Clinical Infectious Diseases Volume 82 Issue 6
临床传染病学 82卷 6期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（传染病艺术长河）
1
Cover Illustration for Camus' The Plague, 1948
加缪《鼠疫》封面插画，1948年
Michael B Grizzard and Mary Grizzard
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page i, https://doi.org/10.1093/cid/ciag182
In the Literature（文献札记）
2
In the Literature
文献札记
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag181
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Contemporary Ambulatory Approach to Adult Fever of Unknown Origin
前沿综述：成人不明原因发热的当代门诊诊疗方案
William F Wright and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 909–926, https://doi.org/10.1093/cid/ciag158
Ethics Rounds（伦理巡诊）
4
Antibiotics in Hospice: Applying the Four-Quadrant Approach to Improve Patient-Centered Care
安宁疗护中的抗菌药物使用：运用四象限诊疗模式优化以患者为中心的照护
Patrick D Crowley and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 927–930, https://doi.org/10.1093/cid/ciag057
Voices of ID（传染病之声）
5
I Died—and Was Brought Back to Life—Twice
我两次濒死，又重获新生
Richard E. Sutton
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 931–933, https://doi.org/10.1093/cid/ciaf612
Antimicrobial Resistance and Stewardship（抗生素耐药与管理）
6
Using Encounter-Level Data for Risk-Adjustment of Antimicrobial Use Comparisons: Feasibility and Variable Selection
利用就诊层面数据开展抗菌药物使用对比的风险校正：可行性与变量筛选研究
Rebekah W Moehring and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 934–943, https://doi.org/10.1093/cid/ciaf682
7
Moving Closer to Patient-Level Risk Adjustment for Hospital Antimicrobial Use
推进住院患者抗菌药物使用的个体化风险校正体系构建
Jonathan D Baghdadi and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 944–945, https://doi.org/10.1093/cid/ciaf683
8
Macrolide and Nonmacrolide Resistance After 36 Months of Mass Azithromycin Distribution in Burkina Faso: A Cluster Randomized Trial
布基纳法索大规模阿奇霉素分发36个月后大环内酯类与非大环内酯类耐药情况：一项整群随机对照试验
Catherine E Oldenburg and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 946–953, https://doi.org/10.1093/cid/ciag051
9
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients: A Pragmatic, Randomized Trial
基于社区获得性肺炎发病概率为住院患者个体化选用抗菌药物：一项实用性随机对照试验
Jonathan D Baghdadi and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 954–961, https://doi.org/10.1093/cid/ciag126
10
ALARA in Antimicrobial Stewardship: Adapting Radiation Safety Principles to Address Antibiotic Overuse
抗菌药物管理中的ALARA原则：借鉴辐射安全理念管控抗生素过度使用
Zachary T Aldewereld and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 962–967, https://doi.org/10.1093/cid/ciaf688
Clinical Practice and Policy（临床实践与医疗政策）
11
Assessment of an Infectious Disease eConsult Service at a Large Mid-Atlantic Healthcare System
美国中大西洋大型医疗体系感染病线上会诊服务应用效果评估
Ava Hunt and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 968–970, https://doi.org/10.1093/cid/ciaf736
12
H.U.S.T.L.E: A Consult Fitness Guide for Infectious Diseases Providers
H.U.S.T.L.E指南：感染科医师会诊工作实操指南
Gonzalo Bearman and Priya Nori
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 971–975, https://doi.org/10.1093/cid/ciaf672
13
More Than a Message: Death by a 1000 “Chats”
不止简单文字沟通：无休止线上问诊带来的诊疗困境
Darcy Wooten and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 976–978, https://doi.org/10.1093/cid/ciag094
14
The Erosion of a Pillar of Public Health: ACIP's Role and the Future of US Vaccine Policy Post-June 2025
公共卫生支柱职能削弱：美国免疫实践咨询委员会的职能变迁与2025年6月后疫苗政策走向
Edwin J Asturias and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 979–985, https://doi.org/10.1093/cid/ciag042
15
Worldwide Impact of ACIP's 2025 Overhaul
2025年美国免疫实践咨询委员会政策修订的全球影响
Louis Bont and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 986–987, https://doi.org/10.1093/cid/ciag043
Hepatitis（肝炎）
16
Trends in Reflexive Hepatitis C Virus Testing in a National US Laboratory: A Retrospective Study From 2018 to 2024
美国国家级实验室丙型肝炎病毒 reflex联动检测趋势：2018–2024年回顾性研究
Min Kyung Lee and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 988–992, https://doi.org/10.1093/cid/ciag227
17
Sofosbuvir/Velpatasvir Concentrations in the Breastmilk of Postpartum Women With Opioid Use Disorder Receiving Treatment for Hepatitis C Virus: A Pharmacokinetic Study
合并阿片类物质使用障碍的产后丙肝治疗女性母乳中索磷布韦/维帕他韦药物浓度：药代动力学研究
Catherine A Chappell and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 993–996, https://doi.org/10.1093/cid/ciaf443
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
18
Incidence of Community-acquired Pneumonia and Herpes Zoster in People With HIV Based on CD4 Count and Age in the Current Antiretroviral Therapy Era: A Longitudinal Cohort Study
当前抗逆转录病毒治疗时代，基于CD4计数与年龄划分的HIV感染者社区获得性肺炎、带状疱疹发病风险：一项纵向队列研究
Elsemieke te Linde and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 997–1006, https://doi.org/10.1093/cid/ciaf686
19
Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance
病毒学抑制HIV感染者转换为比克替拉韦/丙酚替诺福韦/恩曲他滨方案或多替拉韦+富马酸替诺福韦二吡呋酯/恩曲他滨方案：有无替诺福韦耐药人群真实世界转归
Alain Makinson and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1007–1014, https://doi.org/10.1093/cid/ciaf726
20
Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles
HIV感染者转换长效卡博特韦/利匹韦林后的乙肝转归：病毒再激活、新发感染及不同血清学状态下肝脏安全性
Alberto Foncillas and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1015–1022, https://doi.org/10.1093/cid/ciag023
21
Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications
长效注射卡博特韦联合利匹韦林治疗发生病毒学失败：亚型、血药浓度、耐药突变及临床诊疗意义分析
Maria Mazzitelli and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1023–1031, https://doi.org/10.1093/cid/ciag046
22
What Are the Causes and Consequences of Virological Failure on Long-acting Cabotegravir/Rilpivirine?
长效卡博特韦/利匹韦林方案病毒学失败的诱因与临床后果
Andrew Hill and Chloe Orkin
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1032–1034, https://doi.org/10.1093/cid/ciag047
Parasitic Infections（寄生虫感染）
23
Cerebral Malaria and Severe Malarial Anemia, but not Other Forms of Severe Malaria, Are Associated With Long-Term Cognitive Impairment
脑型疟疾与重症疟疾性贫血（其余重症疟疾亚型除外）与远期认知损伤相关
Paul Bangirana and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1035–1041, https://doi.org/10.1093/cid/ciaf712
24
Not All Forms of Severe Malaria Impair Long-term Cognition—More Characterization, More Questions
并非所有重症疟疾均会造成长期认知损害——仍需更多分层研究与探索
Karl B Seydel and Stephen T J Ray
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1042–1043, https://doi.org/10.1093/cid/ciaf713
25
Frequent Plasmodium ovale Recurrence in Coastal Tanzania
坦桑尼亚沿海地区卵形疟原虫高复发率研究
Kelly Carey-Ewend and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1044–1051, https://doi.org/10.1093/cid/ciag199
26
Invisible Malarias
隐匿性疟疾
J Kevin Baird
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1052–1053, https://doi.org/10.1093/cid/ciag201
Sexually Transmitted Infections（性传播疾病）
27
A Pilot, Randomized Controlled Trial of Dual Daily HIV and Sexually Transmitted Infection Pre-exposure Prophylaxis Using Tenofovir Disoproxil Fumarate/Emtricitabine and Doxycycline in Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women: The DuDHS Study
男男性行为人群及跨性别女性每日口服HIV联合性病暴露前预防（富马酸替诺福韦二吡呋酯/恩曲他滨加多西环素）先导随机对照试验：DuDHS研究
Troy Grennan and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1054–1062, https://doi.org/10.1093/cid/ciaf043
28
A New Choice for Doxycycline Prophylaxis
多西环素暴露前预防新选择
Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1063–1064, https://doi.org/10.1093/cid/ciaf044
29
Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial
服用多西环素暴露后预防男性的耐药淋病奈瑟菌感染情况：ANRS 174 DOXYVAC子研究
Béatrice Berçot and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1065–1074, https://doi.org/10.1093/cid/ciaf591
30
Sustained Effectiveness of Doxycycline Post-Exposure-Prophylaxis in a Large Sexual Health Clinic Over 96 Weeks: An Interrupted Time Series Analysis
大型性病诊疗中心多西环素暴露后预防96周持续有效率：间断时间序列分析
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1075–1078, https://doi.org/10.1093/cid/ciaf234
Photo Quiz（影像问答）
31
A 3-Year-Old Girl With a Chest Wall Mass
3岁女童胸壁肿块一例
Deema Gashgarey and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1079–1081, https://doi.org/10.1093/cid/ciag028
32
Why Are Gonorrhea Case Rates Declining in the United States? A Research Agenda
美国淋病报告病例数下降原因：后续研究方向展望
Kirstin I Oliveira Roster and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1082–1090, https://doi.org/10.1093/cid/ciaf690
33
Fever in a Man with Uncontrolled HIV
HIV控制不佳男性发热病例
Tristan Jones and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1091–1095, https://doi.org/10.1093/cid/ciag056
Antimicrobial Resistance and Stewardship（抗生素耐药与管理）
34
Human Cases of Carbapenemase-Producing Escherichia coli Linked to Spread Between Animals and the Environment in a Veterinary Facility—Massachusetts, USA, 2023
2023年美国马萨诸塞州：动物诊疗机构内动物与环境传播引发人感染产碳青霉烯酶大肠埃希菌病例
Ian M DeStefano and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1138–e1144, https://doi.org/10.1093/cid/ciaf541
35
Carbapenemase-Producing Enterobacterales in Pets: A New Threat From Veterinary Clinics
宠物携带产碳青霉烯酶肠杆菌目细菌：动物诊所带来的新型感染威胁
Vincent Perreten and Andrea Endimiani
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1145–e1147, https://doi.org/10.1093/cid/ciaf544
36
Direct Oral Challenge for Penicillin Allergy: The International Network of Antibiotic Allergy Nations (iNAAN) Study
青霉素过敏口服药物激发试验：国际抗生素过敏协作网络（iNAAN）研究
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1148–e1162, https://doi.org/10.1093/cid/ciag082
37
Direct Oral Challenge for Penicillin Allergy: A Hospital Implementation Evaluation Via the International Network of Antibiotic Allergy Nations (iNAAN) Study
青霉素过敏口服激发试验院内落地实施效果评估——基于国际抗生素过敏协作网络（iNAAN）研究
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1163–e1170, https://doi.org/10.1093/cid/ciag083
Bacterial Infections（细菌感染）
38
Clinical Manifestations, Long-Term Trends, and Risk Factors for Treatment Failure in Native Vertebral Osteomyelitis: A 26-Year Mayo Clinic Experience
原发性椎体骨髓炎临床表现、26年长期发病趋势及治疗失败危险因素：梅奥诊所单中心经验
Takahiro Matsuo and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1171–e1180, https://doi.org/10.1093/cid/ciag048
39
The Management of Native Vertebral Osteomyelitis Remains Unchanged: Are Additional Trials Necessary?
原发性椎体骨髓炎诊疗方案无实质性更新：是否仍需开展更多临床试验？
Werner Zimmerli
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1181–e1183, https://doi.org/10.1093/cid/ciag049
40
Clinical Characteristics and Survival of Hospitalized Anthrax Patients with Pleural, Pericardial, or Peritoneal Fluid Collections
合并胸腔、心包、腹腔积液的住院炭疽患者临床特征与生存预后
Jon-Erik C Holty and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1184–e1193, https://doi.org/10.1093/cid/ciag113
41
Uncomplicated Urinary Tract Infections: From an Invisible Impact to a Visible Change in Complex Care
单纯性尿路感染：从隐匿疾病负担到复杂诊疗体系的诊疗变革
Rafael Cantón and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1194–e1199, https://doi.org/10.1093/cid/ciaf705
Emerging Infections（新型感染）
42
Six Cases of Borealpox and Evidence of a Zoonotic Source: Alaska, 2020–2023
2020–2023年阿拉斯加6例北极痘病例及动物源性传播证据
Eric Q Mooring and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1200–e1207, https://doi.org/10.1093/cid/ciaf497
43
Measles Without Rash During Acute Febrile Illness Surveillance in Tanzania, 2023–2024
2023–2024年坦桑尼亚急性发热监测中无皮疹麻疹病例
Saning'o Lukumay and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1208–e1215, https://doi.org/10.1093/cid/ciaf582
44
Melioidosis Complicated by Native Valve Endocarditis in a Traveler Returning From Thailand to the United States
泰国归国旅行者罹患类鼻疽合并原生瓣膜心内膜炎
Akash Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1216–e1221, https://doi.org/10.1093/cid/ciag003
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
45
Hepatocellular Carcinoma Survival in People With and Without HIV in the United States, 2001–2019
2001–2019年美国HIV阳性与阴性人群肝细胞癌生存预后对比
Jennifer K McGee-Avila and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1222–e1231, https://doi.org/10.1093/cid/ciag137
46
Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa
多替拉韦方案对比依非韦伦方案抗逆转录病毒治疗重大心血管不良事件风险：基于南非匿名常规医疗数据的模拟目标试验
Jienchi Dorward and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1232–e1241, https://doi.org/10.1093/cid/ciag155
47
Patterns of HIV-1 Viral Load Suppression and Drug Resistance During the Dolutegravir Transition: A Population-based Longitudinal Study
全面切换多替拉韦治疗期间HIV-1病毒载量抑制水平与耐药突变特征：一项人群纵向研究
Michael A Martin and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1242–e1251, https://doi.org/10.1093/cid/ciag161
48
Renal and Cardiovascular Complications Following Type 2 Diabetes Mellitus in People With and Without HIV: Data From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) Between 2010 and 2024
合并2型糖尿病的HIV感染者与非感染者肾脏及心血管并发症：瑞典HIV发病队列研究（COSMOHS）2010–2024数据
Isabela Killander Möller and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1252–e1261, https://doi.org/10.1093/cid/ciag261
49
Progression Risk in Cancer Patients with HIV Compared with Cancer Patients Without HIV
HIV阳性肿瘤患者相较于阴性患者的疾病进展风险
Derek Schneider and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1262–e1265, https://doi.org/10.1093/cid/ciag170
Infections in Older Adults（老年人群感染）
50
Burden of Respiratory Syncytial Virus Among Older Adults With an Acute Respiratory Infection: A Prospective Study in Six European Countries
急性呼吸道感染老年患者呼吸道合胞病毒疾病负担：欧洲六国前瞻性研究
Manel Terns Riera and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1266–e1276, https://doi.org/10.1093/cid/ciag146
51
Health-related Quality of Life in European Older Adults with Respiratory Syncytial Virus Over Three Respiratory Syncytial Virus Seasons
连续三个流行季欧洲老年呼吸道合胞病毒感染者健康相关生活质量调查
Manel Terns Riera and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1277–e1288, https://doi.org/10.1093/cid/ciag147
52
The Renaissance of Respiratory Syncytial Virus Diagnosis: How Understanding Burden Can Inform Clinical Practice and Demonstrate the Benefit of Vaccines
呼吸道合胞病毒诊断技术革新：明晰疾病负担指导临床实践、印证疫苗获益价值
Angela R Branche
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1289–e1291, https://doi.org/10.1093/cid/ciag148
Mycobacterial Infections（分枝杆菌感染）
53
Hidden in Success: Gendered Patterns of Suboptimal Care Engagement Among Tuberculosis Patients Who“Successfully” Completed Treatment in South Africa
治愈背后的隐忧：南非“治疗成功”结核患者就医依从性的性别差异
Andrew Medina-Marino and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1292–e1301, https://doi.org/10.1093/cid/ciaf714
54
Prevalence and Predictors of Tuberculosis in Adults and Adolescents With Sputum Trace Ultra Results in 2 High-Burden Clinical Settings
两大高结核负担临床中心痰Xpert Ultra微量阳性成人及青少年结核患病率与预测因素
Caitlin Visek and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1302–e1310, https://doi.org/10.1093/cid/ciag019
55
“Trace-MTB” on Sputum Xpert Ultra: New Evidence for Interpretation in High-burden Settings
痰Xpert Ultra“微量结核分枝杆菌”阳性：高结核负担地区判读新证据
Bianca Sossen and Neil Martinson
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1311–e1312, https://doi.org/10.1093/cid/ciag018
56
Diagnostic Accuracy of Molecular Testing on Saliva and Oral Swabs for Pulmonary Tuberculosis
唾液与口腔拭子分子检测对肺结核的诊断效能
Deninson Alejandro Vargas and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1313–e1321, https://doi.org/10.1093/cid/ciag055
57
Documenting Environmentally Acquired Mycobacterium intracellulare subsp. chimaera Pulmonary Disease Soon After Bronchiectasis Onset
支气管扩张发病后短期内确诊环境源性奇美拉胞内分枝杆菌肺病病例报道
Jennifer R Honda and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1322–e1325, https://doi.org/10.1093/cid/ciag015
58
We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness
我国对贝达喹啉耐药危机应对准备不足：呼吁完善临床与公共卫生防控体系
Gail Brenda Cross and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1326–e1332, https://doi.org/10.1093/cid/ciag008
Respiratory Infections（呼吸道感染）
59
Long-term Clinical Outcomes After Hospitalization for Acute Respiratory Illness Due to Respiratory Syncytial Virus
呼吸道合胞病毒急性呼吸道感染住院患者远期临床结局
David Singer and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1333–e1344, https://doi.org/10.1093/cid/ciaf710
60
Microbial Detection in Community-Acquired Pleural Space Infections Using the BIOFIRE Joint Infection Panel and Individual Polymerase Chain Reaction Assays
采用BIOFIRE关节感染试剂盒与单重PCR检测社区获得性胸腔感染病原体
Portia Mira and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1345–e1352, https://doi.org/10.1093/cid/ciag050
61
Diagnostic Performance of New Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis Infection: An Updated Systematic Review and Meta-analysis
新型商业化γ干扰素释放试验诊断结核分枝杆菌感染的效能：更新系统综述与荟萃分析
Lika Apriani and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1353–e1364, https://doi.org/10.1093/cid/ciag102
Viral Infections（病毒感染）
62
Symptomatic and Asymptomatic Norovirus Infections in Early Life; the PREVAIL Cohort, 2017–2020
婴幼儿诺如病毒显性与隐性感染：PREVAIL队列2017–2020年数据
Julia M Baker and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1365–e1374, https://doi.org/10.1093/cid/ciag033
63
Age-Specific Risk of Herpes Zoster in Adults Aged ≥18 Years With Comorbid Conditions—A Retrospective Cohort Study in the United States
≥18岁合并基础疾病成人带状疱疹分年龄发病风险：美国回顾性队列研究
Rachel A Cohen and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1375–e1383, https://doi.org/10.1093/cid/ciag095
64
Herpes Simplex Virus Type 1 Encephalitis: A Prospective Population-Based Cohort Study
1型单纯疱疹病毒性脑炎：一项基于人群的前瞻性队列研究
Lærke Storgaard Duerlund and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1384–e1392, https://doi.org/10.1093/cid/ciag136
Photo Quiz（影像问答）
65
Multifocal Cutaneous Abscesses
多发皮肤脓肿病例
Shrruthi Velavan and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1393–e1396, https://doi.org/10.1093/cid/ciag074
Correspondence（读者来信）
66
New French Guidelines on Subcutaneous Antibiotic Therapy: A Response to Di Bella et al.
法国皮下注射抗生素新版指南发布——回应Di Bella等人研究
Emmanuel Forestier and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1397–e1398, https://doi.org/10.1093/cid/ciag088
67
Time to Appropriate Therapy and Antimicrobial Resistance-Attributable Mortality
抗菌药物及时给药时长与耐药相关死亡风险
Tatsuhiko Nanri and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page e1398, https://doi.org/10.1093/cid/ciag087
68
Is Time to Appropriate Therapy a Mediator of Mortality Associated With Antimicrobial Resistance?
抗菌药物及时给药时长是否介导耐药相关死亡风险？
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1398–e1399, https://doi.org/10.1093/cid/ciag090
69
Request for Additional Details on the COPAT Trial
恳请补充COPAT试验详细研究数据
Brad Spellberg and Bassam Ghanem
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page e1399, https://doi.org/10.1093/cid/ciag100
70
Additional Details on the COPAT Trial
COPAT试验补充研究细节回复
Joy J Juskowich and Arif R Sarwari
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1399–e1401, https://doi.org/10.1093/cid/ciag103
71
Zinc: An Oft-forgotten Component in the Management of Diarrhea
锌剂：腹泻治疗中常被忽视的关键药物
Indi Trehan
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page e1401, https://doi.org/10.1093/cid/ciag111
72
I Zinc, Therefore I Am: Context is Key
锌剂不可或缺：临床应用需结合具体场景
Andi L Shane and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1401–e1402, https://doi.org/10.1093/cid/ciag112
73
When IS900 Positivity is not the Tie-Breaker: Interpreting Mycobacterium avium Subspecies paratuberculosis Signals Across Crohn's Disease and Intestinal Tuberculosis in a Tuberculosis-Endemic Setting
IS900阳性结果不可作为鉴别金标准：结核高发区克罗恩病与肠结核中副结核分枝杆菌判读要点
Yuanli Yang
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1402–e1403, https://doi.org/10.1093/cid/ciag127
74
MAP Detection: Identifying a Pathogenic Driver Rather Than a Diagnostic Marker
副结核分枝杆菌检测：识别致病驱动因素而非单纯诊断标志物
Sudheer Kumar Vuyyuru and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1403–e1405, https://doi.org/10.1093/cid/ciag128
75
Composite End Points, Minor Anomalies, and Missed Work-Ups: Making 12-Month Infant “Unfavorable Outcomes” Interpretable After BDLLfx/BDLCfz in Pregnancy
复合终点、轻微异常与漏诊评估：解读孕期BDLLfx/BDLCfz方案暴露婴儿12个月不良结局
Yuanli Yang
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1405–e1406, https://doi.org/10.1093/cid/ciag142
76
Responding Appropriately to Safety Signals in Infants Exposed to the 6-month BDLLfx/BDLCfz Regimen In Utero
妥善处置宫内暴露6个月BDLLfx/BDLCfz方案婴儿的安全预警信号
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1406–e1407, https://doi.org/10.1093/cid/ciag143
100 项与 盐酸利匹韦林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 2011-05-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 怀孕 | 临床3期 | 美国 | 2009-04-09 | |
| 肝炎 | 临床1期 | 美国 | 2011-11-01 | |
| 丙型肝炎 | 临床1期 | - | 2010-11-01 | |
| 避孕 | 临床1期 | - | 2008-07-01 | |
| 避孕行为 | 临床1期 | - | 2008-07-01 | |
| 获得性免疫缺陷综合征 | 临床1期 | - | 2008-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | 51 | 選遞夢淵鹽網積廠衊網(壓壓醖醖糧範廠簾艱鑰) = 網顧憲獵顧製膚鏇廠繭 鬱醖鏇齋築艱壓顧衊獵 (糧築構鏇鹹廠遞製餘衊 ) 更多 | 不佳 | 2026-07-26 | |||
N/A | 343 | 獵醖鏇願製淵築廠夢窪(鹽憲憲遞艱築獵選獵遞) = 膚憲範窪襯衊願製鏇鏇 蓋淵構艱醖鹽襯醖膚鹹 (糧鹽鑰蓋觸壓鑰憲觸網 ) 更多 | 积极 | 2026-07-26 | |||
獵醖鏇願製淵築廠夢窪(鹽憲憲遞艱築獵選獵遞) = 醖夢簾鹽鏇糧膚鹽鬱艱 蓋淵構艱醖鹽襯醖膚鹹 (糧鹽鑰蓋觸壓鑰憲觸網 ) 更多 | |||||||
N/A | 7,954 | 艱廠醖選淵網築顧鹹壓(糧醖簾憲選艱衊範選顧) = 衊衊遞廠鏇築製夢壓網 繭蓋淵網繭鏇鹹鏇淵糧 (鏇鏇餘窪繭獵選艱膚鬱 ) 更多 | 积极 | 2026-07-26 | |||
艱廠醖選淵網築顧鹹壓(糧醖簾憲選艱衊範選顧) = 鑰構範膚壓糧膚窪顧簾 繭蓋淵網繭鏇鹹鏇淵糧 (鏇鏇餘窪繭獵選艱膚鬱 ) 更多 | |||||||
N/A | 22 | LAI CAB/RPV | 鹹積醖遞衊壓獵壓願顧(壓廠顧繭願窪網窪顧鏇) = three participants discontinued LAI CAB/RPV, all due to injection-site pain 簾艱製夢願構鑰鹹艱淵 (遞網觸積觸範鑰簾顧鑰 ) 更多 | 积极 | 2026-07-26 | ||
N/A | 111 | LAI CAB/RPV (HIV) | 蓋顧構鬱鑰簾蓋蓋鹽襯(鑰觸鹽醖夢築網鹹網鑰) = 夢齋醖壓壓積繭餘獵襯 獵醖製醖糧願艱願夢壓 (窪糧網廠鬱膚構憲襯蓋 ) 更多 | 积极 | 2026-07-26 | ||
临床3期 | 540 | LAI CAB+RPV | 構壓夢獵鑰鏇夢獵餘觸(繭鑰構鏇繭鹽窪獵艱遞): AMD = 0.52, P-Value = 0.336 更多 | 积极 | 2026-07-26 | ||
N/A | 583 | (BMI <30 kg/m²) | 襯齋蓋鹹窪積遞憲衊範(夢鏇衊積窪遞壓範窪願) = 鏇鏇範鏇餘餘鏇鏇網網 鹹衊網顧鏇齋繭衊衊築 (鑰夢範廠艱範構襯醖積 ) 更多 | 积极 | 2026-07-26 | ||
(BMI =30 to <40 kg/m²) | 襯齋蓋鹹窪積遞憲衊範(夢鏇衊積窪遞壓範窪願) = 觸鑰淵鏇鑰構鹹糧遞構 鹹衊網顧鏇齋繭衊衊築 (鑰夢範廠艱範構襯醖積 ) 更多 | ||||||
N/A | 66 | (Viral suppression + HIV) | 窪範膚夢壓範憲鑰鹽衊(願憲鬱顧選網醖鹹鏇窪) = Drug-related adverse events were infrequent. Injection-site pain was mostly mild. 膚範醖鏇範膚製糧鬱廠 (糧網構鏇蓋鹹顧鏇顧壓 ) 更多 | 积极 | 2026-07-26 | ||
临床3期 | 306 | 鹹選選願齋鹹鏇範壓鏇(醖製鏇糧鹹鏇齋夢顧製) = 膚鑰鹽廠艱齋顧膚鹽鬱 繭鑰獵製製蓋繭網顧築 (鑰獵醖鑰製醖觸簾夢窪 ) 更多 | 积极 | 2026-02-26 | |||
Standard care | 鹹選選願齋鹹鏇範壓鏇(醖製鏇糧鹹鏇齋夢顧製) = 膚遞蓋選積壓艱簾遞淵 繭鑰獵製製蓋繭網顧築 (鑰獵醖鑰製醖觸簾夢窪 ) 更多 | ||||||
临床3期 | 396 | Cabotegravir+rilpivirine (CAB+RPV) LA Q2M with a 1-month optional once-daily OLI of CABRPV) LA Q2M with a 1-month optional once-daily OLI of CAB+RPV | 廠顧簾壓襯鏇範觸齋範(觸蓋鑰壓醖觸衊選積獵) = 膚構築鏇積選鹽淵齋觸 蓋簾積築醖鹽鬱簾窪遞 (範襯鑰網窪艱艱鑰鏇製 ) 更多 | 积极 | 2025-12-01 | ||
廠顧簾壓襯鏇範觸齋範(觸蓋鑰壓醖觸衊選積獵) = 遞遞夢廠醖鹹夢壓鏇鹽 蓋簾積築醖鹽鬱簾窪遞 (範襯鑰網窪艱艱鑰鏇製 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用